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33. ABSTRACT
A large number of young adults abuse anabolic androgenic steroids (AAS) to enhance physical Þ tness 
and appearance. Although AAS have been banned in organized sports for nearly thirty years, their use 
remains one of the main health-related problems in sports today because of their availability and low 
price. According to recent statistics of the International Olympic Committee, over half of positive doping 
cases are due to AAS abuse. ConÞ scation of doping substances by Finnish customs authorities increased 
during the 1990s concomitantly with the lower black market prices and easier availability of AAS.
The present study elucidates the adverse effects of AAS abuse. Its focus is on the effects of massive 
doses of AAS when abused with or without other anabolic substances such as growth hormone (GH), 
human chorionic gonadotrophin (HCG) or antiestrogens under authentic conditions.
Twenty-six healthy male power athletes were followed up during their self-regimen of substance abuse 
and during a six-month withdrawal period. None of the volunteers were competitive sports athletes 
subject to doping regulations, and they abused the drugs, which they had obtained from the black 
market, independently of this study.
The results indicate that AAS abuse is dose-dependently associated with myocardial hypertrophy and 
that concomitant use of GH is associated with concentric remodelling of the left ventricle (LV). Despite 
the similar heart size of elite endurance athletes and AAS-abusing power athletes, marked differences 
were present in the electrocardiographic repolarization indices. Thus, QT dispersion was greater in AAS 
abusers in spite of short QT intervals, in contrast to endurance athletes, who had long intervals but less 
QT dispersion. The heart of endurance athletes did not morphologically vary substantially from the heart 
of the subjects abusing AAS, but abuse of AAS resulted in hypertrophy with pathological features.
AAS abuse increases QT dispersion, as measured from a 12-lead electrocardiogram. The autonomic tone 
appears to inß uence QT variables more than the left ventricular mass does. Pathological hypertrophy 
caused by AAS abuse has been suggested to alter repolarization of the myocardium.
Our result support earlier Þ ndings of an AAS-induced decrease in serum high-density lipoprotein 
concentration. AAS also have an inß uence on the by-products of the mevalonate pathway. SigniÞ cant 
increases occurred in serum ubiquinone concentration and the ubiquinone to high-density lipoprotein 
ratio was increased. However, serum dolichol concentration tended to decrease concomitantly with 
high-density lipoprotein concentration during AAS abuse. Supraphysiological doses of AAS enhance 
collagen synthesis, especially in soft connective tissues.
Concomitant abuse of supraphysiological doses of AAS with HCG results in altered semen density. 
Regardless of AAS-induced hypogonadotrophic hypogonadism, HCG maintained spermatogenesis but 
reduced semen quality. Both morphology and motility of semen tended to be impaired. The average 
semen concentration reached normal levels six months after the cessation of substance abuse, although 
serum testosterone levels still tended to be low, especially among those subjects with a longer history of 
anabolic substance abuse.
To sum up, despite the low number of subjects and relatively short follow-up, numerous adverse 
effects were observed, including ventricular tachycardia, transient infertility, atherogenic changes in 
lipoprotein proÞ le and pathological remodelling of the myocardium. The abuse of physical Þ tness-
enhancing substances of all forms should be considered a health risk for young males, which may result 
in both sudden and long-term adverse effects.
4Despite subjects being followed for approximately one year and receiving abundant information 
concerning their health status, none of them discontinued substance abuse after the study, which 
reß ects the difÞ culties in reducing substance abuse with the means of counseling and educational 
programmes.
54. INTRODUCTION
The abuse of anabolic androgenic steroids (AAS) is under constant debate world-wide. A large 
number of young adolescents abuse AAS to improve their physical Þ tness and appearance 
(NIDA 2000). While athletes involved in recreational and minor league sports outnumber top-
level competitive athletes in the abuse of AAS (American Medical Association 1990), AAS are 
nevertheless one of the main health-related problems in organized sports due to their availability 
and low price. According to the International Olympic Committee, AAS abuse is found in over 
50% of positive doping cases (World Antidoping Agency 2002). Moreover, doping tests carried 
out by Finnish anti-doping authorities between 1996 and 2001 showed that 30% of positive results 
were due to AAS abuse (Finnish Antidoping Committee 2002). ConÞ scation of doping substances 
by Finnish customs authorities increased during the1990s (Statistics of Finnish Customs 2002) 
(Figure 1), concomitantly with lower black market prices and easier access to AAS (Figures 2 
and 3). Adolescents who experiment with AAS are also more prone to abuse recreational drugs 
(Nilsson et al. 2001b).
All major tissues, including the brain, have androgen receptors. AAS possess large systemic 
and psychological effects (Haupt 1993, Shahidi 2000). However, when AAS are used at 
supraphysiological doses, the mechanism of action is still under debate. Due to widespread abuse, 
many side-effcts of AAS abuse may turn out to be signiÞ cant risk factors when considering public 
health (Haupt et al. 1984, Yesalis et al. 1989). Many AAS-induced adverse effects are considered 
to be reversible.
6Of particular concern is the increased risk of cardiovascular adverse effects associated with AAS abuse, 
especially among persons predisposed to such events or diseases. Evidence exists that an increasing 
number of premature cardiac events are caused by AAS abuse (Lucas 1993, Taimela & Seppälä 1994). 
According to an epidemiological study among power lifters, the cause for premature cardiac death may 
lie in substance abuse (Pärssinen et al. 2000), though life expectancy among elite athletes on average is 
increased (Sarna et al. 1993).
AAS have profound effects on male endocrinological and reproductive systems. In previous 
studies, AAS-induced lowered male infertility has been found to be reversible. Reported sustained 
hypogonadotrophic hypogonadism caused by steroid abuse has also resolved after withdrawal of 
AAS (Alén et al. 1985b, Yesalis 1993). Prolonged abuse may, however, produce transient testicular 
impairment, observed as lowered steroidogenesis with normal gonadotrophin stimulus (Alén et al. 
1985b, Ruokonen et al. 1985).
Substance abuse is strongly inß uenced by attitudes and trends in society, and recreational abuse is 
hard to control without proper legislation. Substance abuse is strongly associated with peer groups 
and the subgroups involved in Þ tness culture and may be better understood as a life-style. The abusers 
are very aware of the risks of their choice and yet are eager to put themselves at risk without deeper 
consideration. Fitness culture-related substance abuse should be viewed as a public health problem. For 
the previously mentioned reasons, there is a clear need to study the long-term adverse effects connected 
with this kind of life-style. With relevant counseling and adequate doping control, we stand a better 
chance of reducing AAS abuse.
Due to the secretive nature of anabolic substance abuse and for ethical reasons, conducting a study that 
would fulÞ ll all of the criteria of a good clinical trial is difÞ cult. To gain more profound knowledge of 
the health risks of this life-style we must therefore accept certain study limitations. The present study 
elucidates medical aspects of anabolic substance abuse. It was conducted to investigate cardiovascular 
and reproductive risks under authentic circumstances in young adult males who voluntarily predispose 
themselves to anabolic substances.
7
85. REVIEW OF THE LITERATURE
5.1. Pharmacology of anabolic androgenic steroids
5.1.1. Testosterone
Testosterone is a steroid hormone produced by various tissues in the human body although it is 
mainly the product of endocrine glands, i.e. testes, ovaries and adrenal glands. Testosterone synthesis 
is under hypothalamic-pituitary-gonadal-axis control. Testicular steroid production is controlled by 
gonadotrophin, a luteinizing hormone (LH). In men, the majority of testosterone is of gonadal origin, and 
healthy adult males produce between 2.5 and 11 mg of testosterone daily. Male circulating testosterone 
levels are 10-fold higher than female levels. In women, the ovaries and adrenals contribute equally to 
testosterone production, each supplying about 25% of the total circulating level. The remaining 50% 
is derived from peripheral conversion of androstenedione in the liver, skin, brain and adipose tissue 
(RosenÞ eld 1972, Longcope 1986, Gagliardi 1991).
In men about 44% of the secreted testosterone is bound to the sex hormone binding globulin (SHBG), 
and around 2% occurs in free form. The remaining 54% is loosely bound to albumin, from which it can 
dissociate within the capillary beds (Pardridge 1986). Free and bound testosterone exist in equilibrium. 
Through aromatization and reduction, the molecule is converted to estrogen and more androgenic 
5α-dihydrotestosterone, respectively (Huhtaniemi et al. 1992) (Figure 4).
9The testosterone molecule is a four-ring structure of cyclic cholesterol rings. Both reproductive and 
non-reproductive tissues possess possible targets for testosterone. Testosterone has two different kinds 
of biological effects: 1) The androgen effect is responsible for the development of the male reproductive 
organs and secondary sexual characteristics, and 2) the anabolic effect can be seen in increased nitrogen 
Þ xation and protein synthesis (Huhtaniemi et al. 1992).
French physiologist Charles Edouard Brown-Sequard (1889) Þ rst recognized the anabolic effect of a 
testicular extract of dogs and guinea pigs when given subcutaneously. Since the isolation of testosterone 
from testicular extract in 1935, its virilizing properties have been recognized. To increase the therapeutic 
value of the molecule, scientists have been keen on developing molecules with emphasized anabolic and 
prolonged biological activity. Further, to avoid Þ rst-pass metabolism to increase systemic availability, 
the parent molecule needed modiÞ cation, which led to the invention of numerous anabolic steroids 
(NIDA 2000, Shahidi 2001).
5.1.2. Anabolic steroids
To strengthen the anabolic properties of testosterone, more than 100 synthetic steroid derivatives have 
been described for human purposes. The anabolic effect promotes protein synthesis, muscle growth 
and erythropoiesis. In clinical practice, substances with anabolic effect are needed to overcome various 
catabolic states (Shahidi 2001). However, none of these compounds are devoid of androgenicity. 
Androgenic and anabolic properties of anabolic steroids cannot be totally separated. Therefore, it is 
more appropriate to use the term anabolic androgenic steroids (AAS) (Yesalis 1993, Shahidi 2001) 
(Figure 5).
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Testosterone and its derivatives are well absorbed from the gastrointestinal tract but are rapidly 
metabolized during hepatic Þ rst-pass metabolism without reaching systemic circulation. Testosterone is 
inactivated primarily by the cytochrome P450 hepatic isoenzyme (Fotherby & James 1972). To increase 
systemic availability, AAS are modiÞ ed as injectable 17β-esters or orally administered 17α-alkylated 
steroids (Figures 6 and 7). Orally administered testesterone undecanoate also avoids hepatic metabolism 
because it is absorbed from the alimentary canal through the lymphatic system (NIDA 2000).
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After absorption from the gastrointestinal tract during hepatic Þ rst-pass metabolism, testosterone and 
AAS undergo biotransformation and are partly excreted via bile to the faeces. Testosterone in systemic 
circulation is also prone to metabolism in the liver, and once excreted, the steroid can be reabsorbed 
from the gastrointestinal tract. In peripheral tissues, testosterone is susceptible to glucuronization to 
androsterone and etiocholanolone, two major metabolites of testosterone, which are excreted to urine 
(Fotherby & James 1972, Gagliardi 1991) (Figure 4).
In vivo, different AAS are also potential targets for aromatization and reduction. Since the AAS 
molecule is susceptible to such enzymatic conversion, it possesses various biological properties (Yesalis 
1993, NIDA 2000).
5.1.3. Mechanism of action
The effects of AAS on genes and consecutive gene expression are poorly understood. Recently, human 
myostatin has been cloned and is considered to be a negative regulator of muscle growth. Basaria et 
al. (2001) speculated that AAS might act by inß uencing myostatin concentration. Further, all tissues 
are susceptible to androgen action. No tissues are devoid of androgen receptors, and all androgen 
receptors distributed throughout the body possess the same binding afÞ nity for a particular steroid. 
Receptor-binding studies have not demonstrated marked differences between AAS in receptor-binding 
afÞ nity. Young adolescents are more susceptible to androgen action of AAS because they possess a 
higher number of cytosol androgen receptors. Even with the biologically active unbound fraction of 
testosterone in circulation, androgen receptor sites are already saturated in striated muscles (Sheridan 
1983, Huhtaniemi et al. 1992, NIDA 2000, Shahidi 2000)
Supraphysiological doses of AAS induce gain in muscle size and strength, even without concomitant 
exercise (Alén at al. 1984, Bhasin et al. 1996, Giorgi et al. 1999). At a supraphysiological dosage, AAS 
interacts with various receptors, including progesterone, estrogen, and mineralo- and glucocorticoid 
receptors (NIDA 1990, Jänne et al. 1993). Supraphysiological doses of AAS have been speculated 
to mediate their anabolic action through interaction with glucocorticoid receptors by preventing 
glucocorticoids catabolic effect (Hickson et al. 1990, Rogol & Yesalis 1992, Haupt 1993). Testosterone 
has in fact been shown to have a high afÞ nity for glucocorticoid receptors and in vivo it acts as an 
antagonist to endogenous circulating glucocorticoids (Danhaive & Rousseau 1986, 1988).
AAS lower the levels of certain hormone-binding proteins in circulation. Thyroxin, cortisol, sex 
hormone, growth hormone and D-vitamin-binding globulin concentrations in circulation are decreased 
after AAS administration (Barbosa et al. 1971, Small et al. 1984, Ruokonen et al. 1985, Alén et al. 1987, 
Karila et al. 1998). Alterations in carrier protein concentration levels may increase biologically active 
steroid concentrations. One could also hypothesize that AAS-mediated anabolism could be partly due 
to increased concentrations of circulating biologically active human growth hormone (GH) and insulin 
like growth factor-I (IGF-I), particularly when supraphysiological doses are used (Hobbs et al. 1993, 
Karila et al. 1998). Alén et al. (1987) found 5 to 60 times higher serum GH concentrations in subjects 
on AAS, even without concomitant use of exogenous GH. Local stimulation of IGF-I may be required 
in the process of anabolic action (Fryburg 1994).  Androgens are known to be needed in local production 
of IGF-I within the skeletal muscle (Mauras et al. 1998). These could partly explain the mechanism 
of action of supraphysiological doses of AAS. On the other hand, these Þ ndings might also provide 
an explanation for the unpredictable adverse effects of AAS (Bahrke et al. 1996, Pärssinen & Seppälä 
2002) (Figure 8).
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5.2. Clinical indications
Anabolic androgenic steroids have established their usefulness in treating various types of anaemia, 
osteoporosis, androgen replacement therapy, muscle-wasting conditions, cachexia caused by various 
cancers, and HIV infection. Long-standing hypogonadism in adult males is associated with reduced 
bone remodelling and decreased bone formation. In treating muscle-wasting disorders with AAS, none 
of AAS preparations has proved to be superior to another (Francis et al. 1986, Strawford et al. 1999, 
Shahidi 2001, Pärssinen & Seppälä 2002). Recently, AAS have been studied for male andropause 
replacement therapy, but more studies are required before AAS can be used broadly for improving the 
quality of life of ageing males (Swerdloff et al. 1992) (Table 1).
5.3. Abuse of anabolic androgenic steroids
AAS abuse is widespread among all social levels of Western countries. While formely restricted to 
competing athletes, it now also impacts on recreational non-competitive adolescent athletes (Duchaine 
1989, Terney & McLain 1990, Korkia & Stimson 1997). In fact, athletes involved in recreational 
and minor league sports outnumber top-level competitive athletes in AAS abuse (American Medical 
Association 1990). Moreover, there is evidence that high doses of AAS are also abused by non-athletic 
subgroups to gain euphoria (Handelsman & Grupta 1997, Kindlundh et al. 1999).
A vast amount of information is available on how to abuse AAS. Information is provided by 
underground steroid manuals and the internet, and peer groups play a particularly important role as an 
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information source for adolescents (Duchaine 1989). Most AAS are acquired from non-medical sources 
such as the black market and gymnasiums (OSullivan et al. 2000, Green et al. 2001).
5.3.1. Epidemiology
In the early 1950s, AAS use spread among power sports, and soon thereafter its beneÞ cial effects on all 
sports demanding peak physical performance were noticed. It is impossible to estimate the extent of AAS 
use in sports during the 1950s and 1960s. Most studies are based on case reports, and epidemiological 
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studies conducted retrospectively cannot fully be trusted due to the negative reputation of AAS abuse 
in sports. The International Olympic Committee included anabolic steroids on a list of prohibited 
substances in 1975 and testosterone in 1982. Despite the use of anabolic steroids being banned in the 
mid-1970s, their abuse continued extensively in numerous sports (NIDA 1990, Yesalis 1993).
Due to the secretive nature of doping, estimating the extent of doping abuse in modern organized 
sports is difÞ cult. The percentage of positive doping test results in the summer Olympic games during 
1976-1988 varied between 0 and 2.9% (NIDA 1990). Of doping tests endorsed by Finnish antidoping 
authorities in 1996-2001, 1.1% were positive. Throughout the world, the majority of positive doping 
test results are due to AAS abuse (World Antidoping Agency 2002). The prevalence of AAS abuse in 
organized sports based on these results is probably underestimated (Duchaine 1989).
All surveys of prevalence of AAS use are directed at adolescents and young adults, who are considered 
the most likely abusers. The non-medical use of anabolic androgenic steroids had increased by 50% 
among male adolescents between 1991 and 1999 in the United States (NIDA 2000). There is also 
contradictory evidence that abuse of AAS among adolescents in the US had decreased from 1988 to 1996 
(Yesalis et al. 1997). Most surveys report that 3-12% of adolescent males living in the Western world 
admit to the former or present use of AAS. Among adolescent females, the prevalence is 1-2% (Yesalis 
& Bahrke 2000) (Table 2). According to a study conducted in Sweden, the size of municipalities does 
not have an effect on prevalence of AAS misuse (Nilsson et al. 2001a). Such Þ ndings may not, however, 
be applicable to Finland. According to the authors knowledge, abuse of AAS is mainly associated with 
urban life-style.
5.3.2. Fitness subculture
During the 1970s non-competitive Þ tness athletes adopted AAS use to improve outlook and physical 
Þ tness. Their motive for substance abuse thus derived from self-image improvement. The reason 
underlying substance abuse may be fulÞ lling social requirements (NIDA 1990, Kindlundh et al. 1999, 
Hartgens et al. 2001). Stimulants, diuretics and anabolic agents, such as adrenergic β
2
-agonists, growth 
hormone and IGF-1, are taken for the same purpose. These recreational Þ tness athletes are aware of 
the adverse effects associated with such practices. Antiestrogens and human chorionic gonadotrophin 
(HCG) are used to avoid these effects (Macintyre 1987, Yesalis 1993, Pärssinen & Seppälä 2002). The 
term multipharmacy can be applied. An essential part of a Þ tness life-style is to follow strict diet and 
exercise regimen (Table 3).
15
5.3.3. Patterns of anabolic androgenic steroid abuse
Substance abuse follows a pattern that aims to optimize performance and minimize adverse effects 
and the development of tolerance, while somehow mimicking the natural hormonal status. Detailed 
information on such practices is easily accessible from a large selection of underground manuals 
that are available through the mail or by internet. These manuals provide volumes of information on 
substance abuse, the only purpose of which is to improve physical Þ tness and appearance. Without 
proper pharmacological and physiological understanding, abusers expose themselves to great danger.
According to the underground manuals, AAS abuse is periodical, referred to as cycles lasting 
6-12 weeks (Duchaine 1989). A typical abuser keeps wash-out period between cycles ranging 
from a couple of weeks to several months. During the wash-out period the body is assumed to 
recover from the cycle without developing a tolerance to AAS (Pärssinen & Seppälä 2002). The 
instructions often ignore the fact that many injectable preparations are long-acting. Furthermore, 
the author has noticed that a recent tendency in Finland is continuous abuse of AAS without 
wash-out periods. The duration of the cycle depends on the availability of substances and the 
level of experience of the abuser. More experienced abusers tend to elevate the AAS doses 
and prolong duration of cycles until they abuse AAS on a more or less continuous basis.
Athletes combine various AAS preparations in a cycle, a process referred to as stacking. The reason for 
this practice lies in the belief that, due to depression of endogenous steroidogenesis, the body requires 
different steroids to mimic the normal hormonal balance. Different steroids are also used during 
different phases of the cycle to avoid development of tolerance (Duchaine 1989). AAS dosing is carried 
out in a pyramidical fashion. At the beginning of the cycle, the dose is elevated to maximal, decreasing 
the amount towards the end of the cycle. This is done in the belief of achieving the full beneÞ t of AAS 
without developing tolerance, and relieving withdrawal symptoms connected with discontinuing the 
drug. 
The abusers usually exceed the AAS doses used in clinical practice by 10 to 100 times. Availability 
and price of AAS on the black market strongly impact on the dosage and preparation used. The black 
market functions according to the rules of demand and supply. AAS abusers often abuse other drugs 
alongside AAS to further improve physical Þ tness and to counteract the adverse effects of AAS with 
self-treatment (Yesalis 1993) (Table 3).
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5.3.4. Public health considerations
Life expectancy of former Finnish elite competitive athletes is longer than that of sedentary controls 
(Sarna et al. 1993). Power training itself does not increase mortality (Sarna et al. 1993), but in an 
epidemiological study conducted by Pärssinen et al. (2000), substance abuse was found to increase 
risk for premature death. The causes of death among the powerlifters were suicide, acute myocardial 
infarction, hepatic coma and non-Hodgkins lymphoma; at least some of these may be related to AAS 
abuse.
Regardless of the abundant and readily available information on health risks associated with AAS 
abuse, the number of abusers is high according to surveys and customs conÞ scations (Finnish Customs, 
www.tulli.Þ ). During 2002 the number of conÞ scations of medical preparations increased by more than 
one third, to 520 cases, and about half of these were doping substances (232). This was also the Þ rst time 
when in 3 cases raw material was found (Finnish Customs, www.tulli.Þ ). Further, the relative amounts 
of growth hormone and growth factors have increased (Custom Authorities, personal communication).
Evidence on the effectiveness of educational programme in Þ ghting against recreational AAS abuse 
is controversial (Goldberg et al. 1990, 1991). After receiving medical advice concerning the adverse 
effects of AAS, only 19% of counselled subjects refused to abuse AAS in the future (OSullivan et 
al. 2000). However, recent studies demonstrate beneÞ cial effects of educational interventions, which 
might reß ect the present generation being more receptive to counselling (Goldberg et al. 1996, Nilsson 
et al. 2001b). During the last decade public awareness of the adverse effects of AAS has increased and 
attitudes have become more negative forwards AAS abuse, even among adolescent athletes involved in 
competitive sports (Seppälä, personal communication).
AAS abuse resulting in addiction is one reason for continuation of substance abuse. After discontinuing 
the abuse, unpleasant withdrawal symptoms often drive users back to steroids. After the AAS cycle, 
abusers have been reported to frequently encounter depressive feelings (Sheridan 1983, Yesalis 1993, 
Pope & Katz 1994, Pope et al. 2000). 
Some individuals have a genetic predisposition to develop depressive symptoms if deprived of androgen 
action (Seidman et al. 2001). Evidence exists that AAS abusers are also more susceptible to use of 
recreational drugs. AAS abuse seems to lower the threshold to experiment with recreational drugs 
(Nilsson et al. 2001).
AAS are prohibited in organized sports. In order to reveal the abuse, doping tests are mandatory. 
Recreational abuse and abuse in non-competitive sports are out of control. The US Congress has 
criminalized AAS abuse and included them as class III controlled substances. Some Western countries 
have acted similarly including Sweden and Finland (Shahidi 2001).
5.4. Anabolic androgenic steroid-induced adverse effects
AAS have been extensively studied. Within clinical dosages, they are well tolerated. Many of the AAS-
induced adverse effects are reversible. Most adverse effects are gender-dependent, females, for instance, 
experiencing virilizing effects (Shahidi 2001). Studies with controlled supraphysiological doses, a 
proper study design and a matching control group have not been published. Adverse effects associated 
with use of supraphysiological doses of AAS are mainly based on case reports and follow-up studies 
without dosage controls. In the literature, there are numerous case reports of myocardial infarction 
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(McNutt et al. 1988, Lyndberg et al. 1991, Ferenchick & Adelman 1992, Appleby et al. 1994, Huie 
1994), coronary atherosclerosis (Mewis et al. 1996), sudden death (Lyndberg et al. 1991, Fineschi 
et al. 2001), congestive heart disease (Ferrera et al. 1992), serious arrhythmia (Appleby et al. 1994, 
Nieminen et al. 1996), atrial Þ brillation (Sullivan et al. 1999), intraventricular thrombosis (Gaede & 
Montine 1992), pulmonary embolus (Gaede & Montine 1992) and arterial and venous thrombosis 
(Ferenchick 1991) associated with AAS abuse.
AAS abuse has also been associated with hepatic dysfunction and various neoplasias. Alén (1985) 
reported that use of AAS signiÞ cantly increased serum concentrations of hepatic aminotransferases, 
although measurements remained within normal limits. He concluded that sustained high-dose use of 
AAS produces mild impairment in liver function. AAS do not, however, cause irreversible damage to 
liver function (Zimmerman & Lewis 1987). Previous reports stating that AAS administration causes 
hepatic dysfunction are mainly based on elevated serum aminotransferase concentrations (Dickerman 
et al. 1999). Cholestatic jaundice is related to use of 17α-alkylated AAS, not to structurally different 
steroids. Peliosis hepatis (dilated hepatic venous sinuses), by contrast, is not related to C17-alkylating, 
but manifesting with testosterone administration (Burger & Marcuse 1952).
In the literature, evidence can be found of AAS promoting tumor formation in mice by enhancing 
the effects of carcinogens (Lesna & Taylor 1986), without the AAS being mutagenic in the Ames test 
(Ingerowski et al. 1981).
AAS have proven to be aetiological factors for some cancers. According to Chen et al. (1997), 
AAS are included as a risk factor for hepatocellular carcinoma together with viral hepatitis, alcohol 
consumption and some genetic factors. Benign hepatic neoplasia, diffuse hyperplasia, nodular 
regenerative hyperplasia and focal nodular hyperplasia have also been attributed to the use of 17α-
alkylated AAS (Ishak & Zimmerman 1987). Histologically, a rare androgen-speciÞ c form of a hepatic 
tumour can be distinguished in man that appears to act more like a benign hepatocellular adenoma 
(Anthony 1975, Craig et al. 1989). Interestingly, these androgen-related tumours have a tendency to 
regress after androgen medication has ceased (Cocks 1981, Drew 1984, McCoughan et al. 1985).
Hepatocellular carcinoma is connected to long-term treatment with AAS (Ishak & Zimmerman 1987). 
However, the malignant nature of AAS-induced hepatocellular carcinoma is questionable since 
regression occurs in the majority of cases after withdrawal of AAS administration (Shahidi 2001). In 
addition, there is contradictory evidence about the role of androgens in prostate cancer (Signorello et 
al. 1997, Heikkilä 1999). AAS have also been associated with development of soft tissue sarcomas 
(Zahm et al. 1997). While clear convincing evidence of the mutagenicity of AAS is still lacking, they 
do at least possess tumour growth-promoting activity.
Depending on the administration route, infections at the injection site of bacterial or fungal aetiology 
have been reported. There is also an increased risk of hepatis and AIDS as a result of shared needles 
and syringes (Rich et al. 1999). AAS abuse is shown to increase the prevalence of acne formation also 
(Kiraly et al 1988).
AAS abuse is associated with various psychiatric and behavioural effects. One-fourth of AAS abusers 
report major mood syndromes, such as mania, hypomania or major depression, while on AAS (Pope 
& Katz 1994). Despite many of the studies in this area suffering from methodological inadequacies, 
they clearly do demonstrate that increased aggression and irritability are associated with AAS 
abuse (Bahrke et al. 1990). Moreover, evidence exists that severity of psychiatric adverse effects is 
dose-related (Porcelli & Sandler 1998). However, contradictory reports suggest that at least some 
psychiatric symptoms are associated with life-style and exercise regimen (Bahrke & Yesalis 1994). 
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Various psychiatric symptoms are related to withdrawal of AAS, and these increase AAS dependence 
(Brower et al. 1991) (Tables 4-6).
Because the present study aimed to elucidate selected somatic adverse effects of AAS abuse, psychiatric 
and behavioural effects were ignored.
5.4.1. Effects on cardiovascular system
The risk for cardiovascular disease has been found to be increased among AAS abusers (Wilson 
1988). Melchert et al. (1995) speculated that AAS-induced cardiovascular changes are related to four 
mechanisms: atherogenic lipoprotein changes; trombogenic changes in the blood coagulation cascade 
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and platelet function; predisposition to vasospasm; and direct cardiotoxicity. Average 24-hour blood 
pressure levels were not elevated in bodybuilders during AAS administration, but chronic AAS abuse 
did result in an abnormal 24-hour blood pressure pattern (Palatini et al. 1996). Evidence about the effect 
of AAS abuse on the function of the left ventricle (LV) is contradictory (Pearson et al. 1986, Urhausen 
et al. 1989, Thompson et al. 1992).
5.4.1.1. Cardiac adaptation to exercise
Physical activity has a signiÞ cant effect on heart size, shape and function that is noticeable even after 
a short exercise period. Six weeks of moderate endurance training results in both hypertrophy and 
dilatation of the LV. These beneÞ cial exercise-induced changes vanish in three weeks after cessation of 
physical activity (Shapiro & Smith 1983, Wight & Salem 1995). LV mass is 45% greater in competitive 
athletes than sedentary controls (Maron 1986). Diastolic function in athletes heart is generally normal 
(Finkelhor et al. 1986, Lewis et al. 1992, Yeater et al. 1996), in contrast to pathological LV hypertrophy, 
like in hypertension, where impaired LV Þ lling is often detected (Post et al. 1994).
Common opinion has previously held that athletes participating in dynamic type endurance sports 
develop larger LV cavity dimensions without a signiÞ cant increase in wall thickness (eccentric 
hypertrophy) (Figure 9), whereas athletes involved in static exertion and exposed to a pressure load 
are more likely to develop greater LV wall thickness without a signiÞ cant increase in cavity dimensions 
(concentric hypertrophy). However, resistance training without AAS produces the same positive effect 
on cardiac dimensions, diastolic function and blood lipids as aerobic training (Yeater et al. 1996). 
Further, echocardiographic studies have shown greater LV wall thickness to be common in endurance 
athletes, while this is often undetectable in athletes engaged in intense power training (Maron 1986, 
Pelliccia et al. 1993). Yeater et al. (1996) also reported that LV internal diastolic diameter was similar 
in endurance athletes and power athletes with or without AAS use. Karjalainen et al. (1997) have 
speculated that despite similar training and exercise capacity considerable differences in LV mass 
and geometry are present among top-level endurance athletes and that this could be due to genetic 
predisposition. Recently, it was shown that angiotensinogen gene M235 polymorphism is associated 
with LV mass in endurance athletes (Karjalainen et al. 1999). Despite earlier beliefs about the effect of 
exercise on myocardial morphology, it has been thoroughly documented that LV morphology depends 
on numerous factors.
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5.4.1.2. Anabolic androgenic steroids and cardiac hypertrophy
The heart of males in many species is larger than that of females, even after factoring in difference in 
body weight (Silver 1991). Stolt et al. (2000) reported that LV mass among elite female endurance 
athletes does not signiÞ canty exceed LV mass measured from sedentary male controls, 176 ± 29 g (mean 
± SD) vs. 167 ± 37 g, respectively. Experimental studies support the assumption of a direct effect of 
androgens in the heart (Krieg et al. 1978). These Þ ndings are in line with another study that suggests 
that estrogens have a preventive role in the pathogenesis of LV hypertrophy (Lip et al. 2000). Marsh 
et al. (1998) demonstrated the presence of androgen receptors in human cardiac myocytes in both 
sexes and that androgens can directly mediate a signiÞ cant hypertrophic response in cardiac myocytes. 
Experimental studies have shown that prolonged treatment with AAS leads to dose-dependent reversible 
myocardial hypertrophy together with irreversibly reduced compliance of the LV and decreased 
inotropic capacity of the myocardium (Rämö 1987, Karhunen 1988). Nevertheless, similar Þ ndings 
without altered contractility of the heart have also been demonstrated (Trifunovic et al. 1995).
Urhausen et al. (1999) found that among bodybuilders only those using AAS have clearly higher 
hypertrophic indces. Weight training combined with the use of AAS increases LV wall thickness, end-
diastolic volume and mass, and isovolumetric relaxation time is also prolonged signiÞ cantly (De Piccoli 
et al. 1991, Sachtleben et al. 1993, Dickerman et al. 1997a). Deligiannis et al. (1992) demonstrated in 
an echocardiographic study that use of AAS signiÞ cantly increases LV end-diastolic volume (16%) and 
LV mass (17%) as well as total LV volume (17%) in athletes. These augmentations were in proportion 
to the increase in skeletal muscle mass.
LV hypertrophy is an independent risk factor for cardiovascular morbidity and mortality, and it has been 
linked to atrial Þ brillation, ventricular arrhythmia and sudden cardiac death (Lip et al. 2000). Diastolic 
Þ lling is impaired in pathological LV hypertrophic states where the heart is under a pressure load such as 
in aortic stenosis (Fifer et al. 1985). In arterial hypertension, the degree of pathological LV hypertrophy 
is directly related to the impairment of diastolic Þ lling (Fouad et al. 1984). In the literature, discrepant 
results have been obtained for whether AAS abuse-related LV hypertrophy alters diastolic function 
(Urhausen et al. 1989, Yeater et al. 1996). However, Sader et al. (2001) did demonstrate that AAS abuse 
is not signiÞ cantly associated with abnormalities of arterial structure or function.
5.4.1.2.1. Structure of the heart
Spirito et al. (1994), who studied 947 elite athletes, found signiÞ cant gender-related differences in LV 
dimensions. Females elite athletes had a LV diastolic cavity dimension that was 2.0 mm smaller and a 
LV wall thickness 0.9 mm less than age-, body size- and sport- matched males. Among elite athletes, LV 
wall thickness exceeding 13 mm is uncommon (Pelliccia et al. 1991). Pellicicia et al. (1993) concluded 
that the presence of LV wall thickening exceeding 13 mm should suggest an alternative explanation 
to intensive power training. Among elite athletes, 213% possess a LV wall thicker than 13 mm, but 
none exceeds 15 mm (Pelliccia et al. 1991, Henriksen et al. 1996). AAS abuse potentiates concentric 
remodelling of LV hypertrophy (Urhausen et al. 1989, Dickerman et al. 1997a). This concentric increase 
in LV wall thickness is related to body weight and LV mass.
5.4.1.2.2. Histopathological changes
AAS-induced cardiac hypertrophy is associated with similar histopathological changes as those 
encountered in dilated cardiomyopathy (Ferrera et al. 1997). In autopsy samples and myocardial 
biopsies taken after AAS exposure, myocardial Þ brosis and inß ammation have been present (Kennedy 
& Lawrence 1993, Nieminen et al. 1996). Deleterious effects of AAS on myocardial cells depend on 
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the dose administered and the length of exposure (Melchert et al. 1992). Experimental studies with 
myocardial cell cultures reveal cell destruction associated with depressed contractile activity, increased 
lysosomal fragility and depressed mitochondrial activity (Melchert et al. 1992). Further, Tagarakis et 
al. (2000) demonstrated that muscular exercise combined with AAS impairs the cardiac microvascular 
adaptation to physical conditioning. These Þ ndings support a direct toxic effect of AAS on the 
myocardium (Melchert et al. 1995).
5.4.1.3. QT interval and dispersion
QT interval in the electrocardiogram (ECG) is described as the time from onset of ventricular activation 
to the end of electrical recovery. QT dispersion is the dispersion of QT intervals between the leads of 
a 12-lead ECG. It is an indirect measure of the heterogeneity of ventricular repolarization (Zabel et al. 
1995). The lengthening of QT interval among endurance athletes is considered to be due to increased 
vagal tonus or adaptive cardiac hypertrophy (Browne et al. 1982). Lengthening of QT interval predicts 
death in patients with heart disease but not in healthy subjects (Karjalainen et al. 1997). QT dispersion 
exceeding 90 ms increases the risk of cardiac death, resulting in 2.8-fold higher mortality among heart 
failure patients (Anastasiou-Nana et al. 2000). Several studies also suggest that increased QT dispersion 
is associated with increased risk of arrhythmic events (Higham & Campbell 1994, Pye et al. 1994, 
Mänttäri et al. 1997). Furthermore, LV hypertrophy is associated with increased QT dispersion and 
increased mortality in hypertensive patients (Mayet et al. 1996, Perkkiömäki et al. 1996). The athletes 
heart is hypertrophied and often has altered ECG, although no reports are available on QT dispersion 
among top-level athletes.
5.4.1.4. Alteration of lipoprotein proÞ le
 Sex hormones inß uence serum lipoprotein and apolipoprotein concentrations (Morrison et al. 1998). 
AAS alter lipoprotein proÞ le towards atherogenicity (Alén & Rahkila 1984). Sustained use of AAS result 
in profound alterations of serum high (HDL) and low (LDL) -density cholesterol concentrations (Webb 
et al. 1984, Alén et al. 1985a). Glazer (1991) reviewed 15 articles and found that serum HDL levels 
were 40-70% lower due to use of AAS. HDL
2 
fraction was lowered by 80%, and HDL
3
 fraction by 35%. 
There was a concomitant increase of 40% in serum LDL concentration. AAS lowered apolipoprotein 
concentration, mainly via the apo A-I fraction (McKillop & Ballantyne 1987, Glazer 1991). However, 
Cohen et al. (1996) suggested that among male bodybuilders AAS have a beneÞ cial effect on serum 
Lp(a) levels, although the HDL/ LDLratio is reduced. Lipoprotein alterations are assumed to be caused 
by induction of the HDL- catabolizing enzyme hepatic triglyceride lipase (Glazer 1991, Bausserman et 
al. 1997). These lipoprotein proÞ le alterations during AAS administration reverse after discontinuation 
of treatment (Shahidi 2001). While the mechanism is still not resolved, two explanations exist for HDL 
reduction: one is based on AAS androgenic properties and the other is associated with 17α-alkylation.
5.4.1.4.1. Atherogenic changes
Numerous case reports on AAS atherogenicity have been published. Lipoprotein proÞ le alterations due 
to AAS abuse are considered to be an aetiological factor for premature coronary heart disease (Haffner 
et al. 1983, Alén & Rahkila 1984, Webb et al. 1984, Glazer 1991, Mewis et al. 1996). Because low HDL 
levels have a negative correlation with coronary heart disease (Miller & Miller 1975, Mjos et al. 1977), 
AAS abuse is a risk factor of coronary heart disease (Glazer 1991). However, discordant reports claim 
that even though AAS result in marked depression in HDL serum concentration, the use of AAS is not 
associated with signiÞ cant abnormalities of arterial structure or function (Sader et al. 2001). Dickermann 
et al. (1997b) also concluded that despite the signiÞ cantly higher total/HDL cholesterol ratio, the low 
serum total cholesterol levels and low plasma triglyceride levels among AAS abusers raise questions 
22
concerning the exact role of androgens in increasing risk of cardiovascular disease. The assumptions 
are based mainly on epidemiological studies on lipoprotein proÞ le and case reports of sudden cardiac 
events in AAS abusers. Long-term follow-up studies on AAS abusers are needed to reveal causality.
5.4.1.5. Increased risk of cardiovascular events
Several case reports have suggested that AAS abuse is associated with sudden cardiac events such as 
ventricular arrhythmias, acute myocardial infarction and pulmonary embolism (McNutt et al. 1988, 
Ferrera et al. 1997). In epidemiological studies, LV hypertrophy has been cited as an independent risk 
factor for cardiovascular morbidity and mortality (Lip et al. 2000). Pärssinen et al. (2000) concluded 
in their epidemiological study that competitive powerlifters had an increased risk for premature death 
due to suspected substance abuse. Risk of premature death among top-level powerlifters (n=62) was 
4.6 times higher than among the control population. Suicide and myocardial infarction were the main 
reasons for premature death (3 of each, out of 8 deaths). Former elite endurance athletes life expectancy 
is increased mainly due to decreased cardiovascular mortality (Sarna et al. 1993).
Pathophysiological mechanisms of cardiovascular events among AAS abusers have been suggested to 
be the result of enhanced myocardial sensitivity to cathecholamine stimulation, coronary artery disease, 
myocardial Þ brosis and inß ammation as well as enhanced thrombogenesis (Shozawa et al. 1982, 
Ferenchick 1990, Ferenchick et al. 1992b, Kennedy & Lawrence 1993, Nieminen et al. 1996).
5.4.1.5.1. Arrhythmia and sudden death
It is widely accepted that AAS abuse increases risk of sudden death (Kennedy & Lawrence 1993). This 
idea is based on anecdotal evidence relying on case reports. No relevant large-scale follow-up studies 
have, however, been published which could verify causality. The incidence of sudden death among 
young healthy non-substance abusing athletes is ~1/200 000 (Maron et al. 1996), with hypertrophic 
cardiomyopathy being the most common cause (Maron et al. 1995). Different arrhythmias have been 
reported to be associated with abuse of AAS, including atrial Þ brillation and ventricular tachycardia 
(Appleby et al. 1994, Nieminen et al. 1996, Sullivan et al. 1999). LV hypertrophy has also independently 
been associated with development of atrial Þ brillation, ventricular arrhythmias and sudden cardiac 
death (Lip et al. 2000). Despite the lack of large-scale studies, the numerous case reports compellingly 
associate AAS abuse with increased risk of sudden death. In addition, because AAS abuse is not socially 
accepted anamnestic premortal AAS abuse may remain concealed.
5.4.1.5.2. Ischaemic heart disease
In medical literature, many case reports exist of premature acute ischaemic heart disease and myocardial 
infarction related to AAS abuse (Ferenchick et al. 1992, Appleby et al. 1994, Huie 1994). In most of 
the reports, aetiological factors other than previous AAS abuse have been ruled out. However, Fineshi 
et al. (2001) reported two cases where there were no Þ ndings in coronary arteries in autopsy. They 
speculated that a myocardial infarct without vascular lesions is rare and does not prove without doubt 
the direct cardiac toxicity of AAS. They also suggested that studies on AAS action on the neurogenic 
control of cardiac function in relation to regional myocardial contraction and vascular regulation are 
needed. Supraphysiological doses of AAS increase myocardial mass, with this growth likely having 
pathological features, and oxygen consumption is also increased (Deligiannis et al. 1992). One can 
easily conclude that AAS abuse increases the risk of ischaemic myocardial event.
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5.4.2. Effects on metabolic system
5.4.2.1.Effects on non-sterol isoprenoid metabolism
Cholesterol and isoprenoid compounds have a critical and essential role in the growth of all eukaryotic 
cells (Siperstain 1984). Ubiquinone, also known as coenzyme Q
10
 (CoQ
10)
, is a non-sterol isoprenoid 
compound derived as a by-product from cholesterol synthesis (Olson & Rudney 1983). In vivo, 
ubiquinone acts as a lipid-soluble electron carrier in the electron transport chains of the mitochondria 
(Olson & Rudney 1983). It is strongly correlated with the serum LDL cholesterol fraction (Johansen et 
al. 1991). Karlsson et al. (1989, 1990) found that the serum CoQ
10
/LDL ratio remained constant in all 
conditions examined. However, Aberg et al. (1994) demonstrated in rats that serum ubiquinone levels 
could be increased by 20% with probucol without altering serum cholesterol levels. Physical exercise 
also seems to have an inß uence on blood coenzyme Q
10
 concentration and interindividual variation 
exists (Karlsson 1987).
Ubiquinone and its reduced form ubiquinol have been assumed to possess antioxidant properties (Mohr 
et al. 1992). Stocker et al. (1991) have shown that ubiquinol has a powerful antioxidant effect on LDL, 
and therefore, one can conclude that it has an important role in the prevention of atherosclerosis.
Dolichols are α-saturated polyisoprenoid alcohols that are synthesized in microsomes and stored in 
lysosomes (Rip et al. 1985). Polyisoprenoid alcohols are present in all living cells (Rip et al. 1985). The 
liver has an important role in regulating blood dolichol supply (Marino et al. 1994). Phosphorylated 
dolichols function in the biosynthesis of N-linked glycoproteins as a main lipid carrier (Rip et al. 1985). 
Moreover, as free alcohol and fatty acid esters form, they modify ß uidity, stability and permeability of 
biological membranes, and affect the process of fusion (Lai & Schutzbach 1984, Valtersson et al. 1985). 
A linear correlation is present between serum HDL and dolichol concentrations from which it is easy to 
conclude that the dolichols are transported with the HDL fraction (Yasugi & Oshima 1994). Agents that 
inhibit dolichol synthesis can possibly prevent an increase in plasma membrane IGF-I receptors, thus 
potentiating retarded cancer growth by down-regulation of the IGF-I effect. Dolichol and IGF-I appear 
to be essential for angiogenesis (McCarty 2001).
No previous reports of the effects of supraphysiological AAS doses on isoprenoid synthesis and blood 
concentrations exist.
5.4.2.2. Effects on collagen metabolism
AAS have increased collagen synthesis in an in vitro study when applied to human dermal Þ broplasts 
(Falangia et al. 1998). AAS abuse has been suggested to deteriorate the form and function of connective 
tissues (Laseter & Russell 1991). Several case reports indicate that AAS abuse weaken the tendons, 
therefore considerably increases the risk of muscle and tendon ruptures (Bach et al. 1987, Kramhøft & 
Solgaard 1986). Among AAS-abusing athletes, tendon and muscle insertion traumas are suspected to 
be more frequent (Taimela & Seppälä 1994). Experimental studies have shown that high doses of AAS 
produce ultrastructural and biochemical alterations in tendons that may decrease the tensile strength 
of tendons (Michna 1986, Laseter & Russell 1991, Inhofe et al. 1995). Tendon degeneration and the 
development of dysplastic collagen Þ brils have been demonstrated in rats during AAS administration, 
and these effects were most pronounced when exercise was combined with AAS administration (Wood 
et al. 1988). Moreover, the quantity of collagen molecules in tendons is decreased, while the number 
of collagen Þ brils in the extracellular matrix increases. Further, depending on the duration of the AAS 
exposure, the relative number of dysplastic collagen Þ brils in rat tendons increases (Michna 1986).
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Type I collagen is the most abundant collagen type in the body, and its synthesis can be measured by 
serum carboxyterminal propeptide of type I procollagen (PICP), whereas carboxyterminal telopeptide 
of type I collagen (ICTP) reß ects the degradation of type I collagen. Serum PICP has been shown to 
reß ect the remodelling of bone. Serum ICTP implicates the resorption of bone (Risteli et al. 1988, 
Melkko et al. 1990). Metabolism of type III collagen, the major constituent of many dense and most 
loose connective tissues, except bone, tendon and cartilage, can be measured by serum aminoterminal 
propeptide of type III procollagen (PIIINP). PIIINP reß ects the overall metabolism of all soft connective 
tissues in the body (Risteli et al. 1988).
Serum levels of ICTP and PIIINP are reported to increase during hormone replacement therapy with 
nandrolone decanoate (Hassager et al. 1994). This is thought to be due to increased breakdown of 
collagen types I and III in non-bone tissues. ICTP was suggested to derive relatively more from non-
bone tissues than from bone because it did not correlate with histomorphometric measurements of bone 
turnover (Hassager et al. 1994). Oikarinen et al. (1992) found that during corticosteroid treatment the 
serum levels of PICP and PIIINP decreased, suggesting that corticosteroids suppress the synthesis of 
type I and III collagens. AAS at high concentrations may also bind to glucocorticoid receptors, and thus, 
AAS may have an impact on collagens by counteracting the effect of corticosteroid (Rogol & Yesalis 
1992, Haupt 1993).
AAS may also inß uence collagen metabolism by direct stimulation of androgen receptors, which are 
known to be present in low densities in osteoblasts and bone marrow, thus also inderectly inhibiting 
osteoclast precursors and bone resorption. However, most of the androgen effects on bone turnover 
and bone mass occur via the estrogen receptor with prior aromatization of androgens into estrogens 
(Vanderschueren et al. 1995).
5.4.3. Effects on reproductive system
5.4.3.1. Endocrinological effects
AAS are derivatives of testosterone and, via negative feedback to the hypothalamus, they induce 
hypogonadotrophic hypogonadism associated with decreased serum testosterone concentrations (unless 
exogenous testosterone used), testicular atrophy, impaired steroidogenesis and spermatogenesis (Kilshaw 
et al. 1975, Schurmeyer et al. 1984, Jarow & Lipshultz 1990). There is a marked depression of serum 
testosterone and sex hormone-binding globulin (SHBG), especially when C17α-alkylated steroids are 
used, as well as of gonadotrophins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) 
(NIDA 1990, Sader et al. 2001). LH and FSH control steroidogenesis and spermatogenesis, and their 
secretion is regulated by gonadal steroids and inhibin through negative feedback (de Kretser et al. 1998, 
2000). LH and FSH secretion are equally suppressed after 4-6 months of testosterone administration at a 
physiological to moderately supraphysiological dosage (25-300 mg/week) (Matsumoto 1990). Normal 
spermatogenesis requires a 50-fold higher androgen concentration in the testis than in the peripheral 
serum (Adamopoulos et al. 1984, Turner et al. 1984). AAS also induce changes in other hormone levels 
and endocrinological systems, probably mediated by multiple receptor interactions, but these effects 
seem to be reversible (OConnor et al. 1990, Brower 1993).
5.4.3.2. Effects on male fertility
Androgens have been used to treat male subfertility, but inadequate evidence exists to evaluate the 
usefulness of androgens for this purpose (Vandekerckhove et al. 2000). A few studies have also been 
published on AAS abuse-induced impaired fertility during a steroid cycle and following the cessation of 
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abuse. In these reports, lowered fertility has always been reversible (Yesalis 1993). AAS abuse induces 
oligozoospermia and sometimes azoospermia (Schurmeyer et al. 1984). Torres-Calleja et al. (2001) 
showed that abuse of AAS not only reduces the concentration of sperm, but in some subjects also 
impairs the percentage of morphologically normal semen. Lower semen density is supposed to occur 
because of AAS-induced hypogonadotrophic hypogonadism. No reports of the direct effects of AAS on 
testicular semen production are available.
In healthy male subjects, human chorionic gonadotrophin (HCG) used alone at a dosage of 5000 IU 
three times a week can maintain normal spermatogenesis (Matsumoto et al. 1983). The role of FSH 
in spermatogenesis is controversial, but at least it has a qualitative role in human spermatogenesis 
(Tapanainen et al. 1997). However, long-term HCG treatment has been shown to suppress spermatogenesis 
in an experimental model (Cusan et al. 1982), and HCG has a direct effect on spermatogenesis which 
leads to poorer sperm quality (Dunkel et al. 1997). Knowledge of male reproduction is mainly based on 
fertility control studies. Large variability exists in interindividual fertility, and thus the androgen dose 
required to suppress spermatogenesis also varies substantially between individuals (Schurmeyer et al. 
1984, Knuth & Nieschlag 1987). Despite using a moderately large testosterone dosage (300mg/week), 
azoospermia is not reliably achieved in normal men (Matsumoto 1990). Further, this dosage failed to 
stimulate spermatogenesis (Matsumoto 1990).
5.5. Effects of growth hormone on cardiovascular system
Human growth hormone (GH) is a peptide hormone that is segregated from the posterior hypophysis. 
Different forms of GH are present in the circulation. This is a major peptide formed from a chain 
containing 191 amino acids. GH is mainly a regulator of vertical growth until closure of the epiphyseal 
plates, after which it also functions as an anabolic hormone, increasing the bodys overall protein 
synthesis (Pelkonen 1992). Although the effectiveness of GH as an anabolic substance is undisputed, its 
beneÞ t as a performance-enhancing substance in athletes is debatable (Macintyre 1987). Nevertheless, 
the abuse of GH to gain muscle mass and strength has increased due to its better availability since its 
synthetic manufacturing (Macintyre 1987). At present, a doping test to reveal GH abuse is lacking.
GH excess in prepubertal subjects leads to gigantism, and in postpubertal subjects excessive GH 
causes acromegaly. GH excess also has diabetogenic effects (Macintyre 1987). Before the advent 
of recombinant DNA technology, GH was derived from the pituitary glands of human cadavers 
(Biosynthetic growth hormone 1985). Several cases of Creutzfeldt-Jakob disease were attributed to the 
use of cadaver pituitary glands that were infected with this virus (Problems with growth hormone 1985). 
Due to its injectable route of administration, there is an increased risk of hepatis and AIDS as a result of 
shared needles and syringes.
GH directly affects the growth of the heart (Oparil 1985). The GH receptor gene is expressed in 
the myocardium of the rat heart (Mathews et al. 1989). In man, it controls cardiac wall stress and 
performance through its effect on myocardial growth (Fazio et al. 1997). In acromegaly, the majority of 
patients manifest LV hypertrophy even without hypertension (Lie 1980), and aberrant diastolic Þ lling 
has also been reported (Smallridge et al. 1979). Acromegalic heart enlargement does not correlate with 
a persons weight or height (Lie 1980). Among acromegalic patients, the major causes of morbidity and 
mortality are cardiovascular complications such as premature coronary artery disease, hypertension, 
congestive heart failure and arrhythmia (Klein & Ojamaa 1992). Acromegalic patients have a higher 
prevalence and severity of ventricular arrhythmia, the severity of which correlates with LV mass 
(Kahaly et al. 1992). GH concentration does not affect the prevalence of arrhythmia, unlike the duration 
of exposure (Kahaly et al. 1992). Suppressing GH hypersecretion with the somatostatin analogue 
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octreotide improves the hearts systolic and diastolic functional indices at rest (Giustina et al. 1995). 
Moreover, LV mass is reduced with octreotide therapy (Tokgözoglu et al. 1994). However, prolonged 
hypersecretion of GH in acromegalic patients causes irreversible impairment in left ventricle Þ lling 
(Rossi et al. 1992).
In GH-deÞ cient adults, substitution therapy increases LV mass, mainly due to increased LV dimensions, 
but cardiac output is also increased (Caidahl et al. 1994). Contrary reports in which neither structure nor 
function was improved after GH replacement therapy are also available (Nass et al. 1995). The cardiac 
growth-promoting effect of GH has been studied under different conditions. Patients with idiopathic 
dilated cardiomyopathy have been reported to beneÞ t from therapy with recombinant GH. GH therapy 
increases myocardial muscle mass and reduces dimensions of the LV (Lim et al. 1992, Fazio et al. 1996, 
Genth-Zotz et al. 1999). Patients with ischaemic cardiac failure, by contrast, do not beneÞ t from GH 
therapy. No improvement was seen in LV function, either in mass or myocardial perfusion, after six 
months of therapy (Smit et al. 2001).
AAS and GH may have a synergetic effect on the myocardium. In experimental studies, concomitant 
use of androgens with GH increases the effects of both substances on the myocardium (Scow & Hagan 
1965). Krieg et al. (1978) have also speculated that androgen receptor concentration may depend on 
GH concentration, which itself induces signiÞ cant metabolic activities in the heart (Hjalmarson et al. 
1975, Mowbray et al. 1975). Both AAS and GH have a direct impact on the myocardium. Typically 
in anabolic substance abuse, both of those hormones are abused concomitantly. No reports addressing 
possible effects of combined abuse have yet been published.
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6. AIMS OF THE STUDY
This series of studies was conducted to evaluate various effects of abuse of anabolic substances on 
cardiovascular, metabolic and reproductive systems under authentic conditions.
The speciÞ c aims were:
1. To evaluate effects of anabolic androgenic steroid abuse with or without concomitant abuse of 
growth hormone on the size, morphology and function of the myocardium.
2. To reveal potential predictive signs in electrocardiograph depolarization indices of pathological 
growth induced by abuse of anabolic androgenic steroids.
3. To clarify anabolic androgenic steroid-induced alterations in cholesterol synthesis and effects on 
serum isoprenoid concentrations.
4. To elucidate effects of anabolic androgenic steroids on collagen synthesis, degradation and overall 
metabolism, to reveal a possible biochemical mechanism of anabolic androgenic steroids on 
collagen metabolism.
5. To study how abuse of anabolic substances affects male fertility, gonadotrophin plasma 
concentration and spermatogenesis.
28
7. SUBJECTS AND METHODS
7.1 Subjects recruitment
Between March 1992 and August 1994 a total of 26 healthy, non-obese, male power athletes aged 22-40 
years responded to advertisement attached to the bulletin boards of various Þ tness clubs in the Helsinki 
metropolitan area (Table 7). They represented various sports (mainly bodybuilding) that use weight 
lifting as their main training modality. None of the volunteers represented a competitive sport subject 
to doping regulations. Participants abused drugs independently of this study, obtaining them from the 
black market. Subjects were consecutively recruited and all available subjects at the time were included 
in each substudy at the respective starting point.
In Study II, 30 endurance athletes aged 22-31 years with running as their main training modality 
were included as a comparison group. All male runners of the national training group of the Finnish 
Orienteering Association as well as high-ranking long distance male runners (events from 3000 metres 
to marathon) from Southern Finland were invited to take part (participation rate 84%). The mean ± SD 
maximal oxygen uptake of the endurance athletes was 76 ± 5 (range 69-89) ml/kg/min and did not differ 
signiÞ cantly between orienteering and long distance runners.
The control group (Studies I and II) consisted of 15 sedentary men, either Finnish army conscripts or 
physicians, with none exercising more than two hours per week.  Their mean result in the Cooper test 
(distance run in 12 min) was 2730 metres.
All subjects and controls underwent a routine medical examination, and none had a history of any 
chronic diseases or took any continuous medication, except for the power athlete group.
7.2. Ethics
The power athletes were counseled against substance abuse and given written information on adverse 
effects. All subjects and controls provided their written informed consent. The Ethics Committee of 
the National Public Health Institute, Finland, approved the study protocol. All participants signed a 
statement declaring that they were not under ofÞ cial doping control.
7.3. Study design and drugs
The power athletes were followed up during their self-regimen substance of abuse and the subsequent 
withdrawal period. Subjects were asked to maintain a six-month withdrawal, but some subjects did not 
follow these instructions. All subjects kept accurate daily records of the individual preparations and 
doses they used. Since each had an individual drug selection and dosage, the participants were asked 
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to conÞ dentially surrender a sample of the preparation used (Figures 10 and 11). The ingredients of 
various anabolic steroid preparations were determined by mass spectrometry (Donike et al. 1988).
Urine specimens and serum samples were obtained from the subjects once every two weeks during 
substance abuse and the subsequent withdrawal period. A standard screening procedure for AAS was 
performed on each sample using GC/MS (Donike et al. 1988). No discrepancies were present between 
subjects records and the results of chemical analyses.
For comparative purposes, we calculated various AAS doses based on milligrams of preparation used 
(although not all doses are equipotent). There is no way to differentiate AAS by administration route in 
terms of biological effectiveness. However, because the subjects lived in the Helsinki metropolitan area 
and were subject to the same drug availability, similar preparations were abused.
The subjects followed the same physical training regimen throughout the study.
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7.3.1. Study I
Twenty substance-abusing power athletes (16 abusing AAS and 4 AAS and GH) and 15 controls were 
included. Echocardiography and Doppler echocardiography were performed during the last days of the 
AAS cycle. Tests were done between 8:00 and 12:00 after a light breakfast. The subjects did not take 
any medicine on that morning.
Mean AAS dose per day prior to cardiac evaluation was determined by dividing the total cumulative 
AAS dose (in mg) by the duration (days) of the cycle thus far. Both oral and injectable steroid 
preparations were included in the cumulative dose. Four of the subjects took 2-4 international units (IU) 
of GH in the evening on an irregular basis and by subcutaneous injection.
7.3.2. Study II
Fifteen substance-abusing power athletes (11 abusing AAS, and 4 AAS and GH), 30 substance-free 
endurance athletes and 15 controls were included. Twelve-lead ECGs were taken during the last days 
of the AAS cycle. ECGs were done between 8:00 and 12:00 after a light breakfast. The subjects did not 
take any medicine on that morning. Calculations of abused doses were determined as in Study I.
7.3.3. Study III
Thirteen substance-abusing power athletes were included. The average length of AAS administration 
during the study was three months, with the subsequent withdrawal period averaging six months.
Daily steroid dose (mg/day) was determined by calculating the average daily dose during the last ten 
days before a blood sample was drawn. The daily dose of an injectable steroid preparation was obtained 
by dividing the dose contained in each individual injection by the number of days between injections.
Every second week during the abuse cycle and withdrawal period, blood samples were drawn for assay 
of serum ubiquinone and dolichol, total and HDL cholesterol, triglycerides and liver aminotransferases 
(S-ALAT, S-ASAT).
7.3.4. Study IV
Seventeen AAS-abusing power athletes were included. Each subject gave four blood and urine 
samples, two of which were taken during the AAS administration period and two during the subsequent 
withdrawal period. The Þ rst sample was drawn at one month and the second sample at two months after 
the beginning of AAS abuse, and the third and the fourth samples at one and two months, respectively, 
after the cessation of AAS abuse.
Average daily doses of AAS were determined by dividing cumulative dose of AAS (p.o. and i.m. 
included) by duration (days) of the cycle. The weight used for the calculations in statistical analyses was 
the maximum weight measured during the course of the study. All subjects, except one, kept accurate 
records of the drugs and doses used during the AAS administration period. The exception was taken into 
account during statistical analyses.
7.3.5. Study V
Twenty-one substance-abusing power athletes were included. Three of those were excluded; one had 
a history of infertility treatment and the other two withdrew from the study for personal reasons, thus 
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resulting as 18 subjects participating.
Semen samples were obtained by masturbation after 2-7 days of sexual abstinence [95% conÞ dence 
interval (CI) of the mean: 64-94 hours]. The samples were taken at the end of the AAS cycle (sample 1), 
at 1.5 months (95% CI: 39-52 days) after cessation of AAS abuse (sample 2) and at six months  (95% 
CI: 134-185 days) after cessation (sample 3).
Both oral and injectable steroid preparations were included in the calculation of total cumulative AAS 
dose. The mean daily AAS dose was determined by dividing the total cumulative AAS dose by duration 
(days) of the cycle. The HCG dose was calculated as the total cumulative HCG dose (in IU) used during 
the cycle.
To study the effect of AAS dose, the subjects were divided into two groups. Those whose total cumulative 
dose was at or below the median (12 785 mg) were referred to as minor users (n=10), and those whose 
dose was above the median were referred to as major users (n=9). To determine the effect of HCG dose 
on semen variables, the subjects were also divided into another two groups: either below or above 12 
000 IU [n=6 (mean dose 7875 IU) and n=13 (mean dose 32 000 IU), respectively]. The subjects were 
divided into groups based on self-reported information on substance abuse.
The subjects were contacted at 6 ± 0.65 years (mean ± SD) after cessation of the AAS cycle and asked 
about the number of children conceived and successful pregnancies during the period since cessation.
7.4. Echocardiography
Echocardiographic and Doppler measurements were made by the same observer, and obtained directly 
from the screen monitor with the aid of calipers and the instrument trackball. The investigator was 
blinded to drug selection and dosage. Due to marked differences in body shape between subjects, the 
investigator could not be blinded to study groups.
Echocardiographic and Doppler studies were performed with an Acuson 128 instrument and a 2.5  3.5 
MHz transducer. Subjects were positioned at 45 degrees in left lateral position. To avoid including 
trabeculations in the wall thickness measurements, an integrated M-mode and two-dimensional study 
was done to determine interventricular septal and LV posterior wall thickness and LV end-diastolic cavity 
dimension.  First, two-dimensionally targeted M-mode recordings were obtained in parasternal long-
axis view (Sahn et al. 1978). Second, septal and posterior wall thicknesses were measured in parasternal 
long-axis view between mitral valve tips and papillary muscle, from expanded two-dimensional images. 
Smaller numbers from either M-mode or two-dimensional measurements were accepted to represent 
the actual thicknesses of the septum and posterior wall. The LV mass was calculated using the formula 
by Devereux (1987): Mass = 0.8*[1.04*(septal thickness + end-diastolic diameter + posterior wall 
thickness)3- end-diastolic diameter]3+ 0.6 g.
LV length was measured at end-diastole from the apical window at a view maximizing the ventricular 
length. Measurements were made from the mitral valve plane to the apical epicardium (L1) and to the 
apical endocardium (L2). The myocardial cross-sectional area of the LV was the difference between total 
LV area subtended by the epicardium (A1) and LV cavity area (A2) traced using a midventricular short-
axis view at the level of papillary muscle tips. The concentricity or eccentricity of the LV myocardium 
was evaluated by calculating the relative wall thickness (RelWT) using the formula: RelWT=(septum 
thickness + posterior wall thickness)/LV end-diastolic diameter. The sphericity of the LV chamber 
was evaluated by calculating the ratio of LV end-diastolic diameter to ventricular length. In all two-
dimensional measurements, the endocardial/cavity (black-white) interface was used for endocardial 
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border deÞ nition (Schiller et al. 1989). Measurements of LV diastolic Þ lling velocities were obtained in 
an apical four-chamber view by positioning the pulsed Doppler volume sample about 1 cm below the 
mitral annulus.  Early peak ß ow velocity (E) and peak atrial ß ow velocity (A) were measured and the 
ratio E/A calculated.
One power athlete in Study I underwent Doppler echocardiography three times. He was Þ rst examined 
during abuse of AAS and GH, second during the washout period and third during the next AAS cycle.
7.5. Standard 12-lead electrocardiogram and calculations of QT dispersion
The measurements were made from a standard 12-lead resting ECG. QT intervals were measured 
manually from the beginning of the Q wave to the end of the T wave by the same investigator, who 
remained blinded to the group and identity of subjects. The QT dispersion was calculated as the 
difference between the longest and the shortest QT interval. Since QT interval durations were different 
in each group, we also calculated the relative QT dispersion in two different ways:
1) QT dispersion divided by the longest QT interval,
2) Standard deviation of the QT interval divided by mean QT interval.
To compare the length of the QT intervals between groups, QT intervals were adjusted to the heart rate 
using the nomogram method (Karjalainen et al. 1994).
7.6. Clinical chemistry
After the blood samples were drawn, the serum was separated and aliquots stored at -20°C for lipids, 
carboxyterminal propeptide of type I procollagen (PICP), carboxyterminal telopeptide of type I collagen 
(ICTP), aminoterminal propeptide of type III procollagen (PIIINP) and hormones (testosterone, SHBG, 
LH, FSH) and at 70°C for ubiquinone/dolichol assays.
Total cholesterol levels, HDL fraction and serum triglycerides were measured using commercial kits 
from Boehringer-Mannheim Diagnostica (Mannheim, Germany). The HDL fraction was obtained by the 
Mg2+/dextran sulphate precipitation method (Finley et al. 1978), and LDL cholesterol was calculated 
using the Friedewald equation (1972). 
The ubiquinone determinations were performed according to Laaksonen et al. (1995) by high-
performance liquid chromatography (HPLC). The dolichols were analysed by an HPLC-method 
(Jokelainen et al. 1992). The serum levels of dolichols were expressed as the sum of the three 
homologues of 18, 19 and 20 isoprene units.
Analyses for PICP, ICTP and PIIINP were performed with a radioimmunoassay kit (Orion Diagnostica, 
Espoo, Finland)(Risteli et al. 1988, Melkko et al. 1990, Risteli et al. 1993).
Spot urine samples collected in the afternoon were used for the quantiÞ cation of hydroxylysyl 
pyridinoline (HP) and lysylpyridinoline (LP) mature crosslinks of collagen. The HP/LP analysis 
was performed using equipment from Merck Hitachi according to Eyre et al. 1984, Black et al.1988, 
Palokangas et al. 1992). The results of HP and LP were given after comparison with standards, which 
were prepared from bovine cortical bone (Cheng et al. 1996) and calibrated with the aid of the authentic 
HP and LP standards kindly provided by Dr. Simon Robins (The Rowett Research Institute, Aberdeen, 
Scotland). The HP and LP results are expressed as µmol/mol creatinine. Creatinine (Cr) was quantiÞ ed 
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in the unhydrolysed urine samples by the Jaffé procedure using a commercial reagent kit (Boehringer-
Mannheim).
Total testosterone was determined in untreated serum by radioimmunoassay using a commercial 
kit (Coat-a-Count®) obtained from Diagnostic Products Corp., Los Angeles, CA, USA. Serum 
concentrations of LH and SHBG were determined by time-resolved ß uoroimmunoassay (TRFIA) using 
commercial kits (DelÞ a®) obtained from Wallac Ltd., Turku, Finland. Serum FSH was determined by 
immunoluminometric assay using a commercial kit (ACS FSH®) obtained from Ciba-Coming Corp., 
MedÞ eld, MA, USA.
7.7. Semen analyses
Semen analyses were carried out according to World Health Organization guidelines (World Health 
Organization Laboratory manual for the examination of human semen and semen-cervical mucus 
interactions, Cambridge WHO). Analyses of the concentrations and motility were, however, carried out 
using a Makler chamber at room temperature. The criteria for normozoospermia were a concentration 
of ≥ 20 x 106/ml, grade motility in 25% or grade A+B motility in 50% of spermatozoa, and normal 
morphology (in stained preparations) in at least 30% of spermatozoa.
7.8. Statistical methods
The results are expressed as mean ± standard deviation (SD), and 95% conÞ dence intervals (CI) for the 
mean (Study I) or median (for semen variables, Study IV) are also given.
In Study I, non-parametric Kruskal-Wallis analysis of variance (ANOVA) was used to assess the 
statistical differences between the three groups, and when appropriate, multiple comparisons were made 
using the Mann-Whitney U-test with Bonferroni correction.
In Study II, one-way ANOVA was used to assess statistical differences between the three groups, and 
when appropriate, post hoc analyses were carried out using the LSD test.
In Study III, the results were recalculated from the original article. The mean for each subject during 
the AAS abuse and withdrawal period was calculated. After careful re-evaluation of the samples and the 
subjects, 8 subjects were included in the AAS group and 11 in the off AAS group. Wilcoxon´s paired test 
(n=8) was used for evaluation of the signiÞ cance of differences between the groups.
In Study IV, the results were recalculated from the original article. The repeated measure of ANOVA 
was used to assess the statistical differences between the four samples, and when appropriate, post hoc 
analyses were carried out using Students t-test to assess the statistical differences between the groups.
 In Study V, the repeated measure of ANOVA was used to assess the statistical differences between the 
three samples and different groups, and when appropriate, post hoc analyses were carried out using 
Students t-test to assess statistical differences between groups. 
Pearsons correlation coefÞ cients were calculated to assess the associations between echocardiographic 
measurements and various subject characteristics (Study I), AAS doses and serum PICP, ICTP and 
PIIINP and urine HP, LP and creatinine concentrations (Study IV), and semen variables and various 
subject characteristics (Study V). Spearman´s correlation coefÞ cients were calculated to assess any 
relationship between the daily steroid dose (n=8) and serum ubiquinone, dolichol, cholesterol, HDL and 
LDL (n=11).
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The determinants of LV mass (Study I) and anomalous spermatozoa (Study V) were studied using 
forward stepwise multiple regression analysis with α-to-enter = 0.150 and α-to-remove = 0.150.
In Study IV, the data on the subject who failed to supply accurate records of the drugs and doses used 
during the AAS administration period were not used when comparing the doses with other parameters. 
Probabilities of less than 0.05 were regarded as statistically signiÞ cant. Statistical analyses were carried 
out using the software program Systat (1992) for Windows, and for Study II, the analyses were carried 
out using StatSofts Statistica for Windows release 5.1.
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8. MAIN RESULTS
8.1. Effects on left ventricular mass, geometry and Þ lling
LV mass, height-indexed LV mass, RelWT, and septum and posterior wall thicknesses were all 
signiÞ cantly greater in subjects using both AAS and GH (n=4) than those using only AAS (n=16) 
or among the sedentary controls (n=15) (Table 3, Study I). Moreover, all of these parameters were 
signiÞ cantly higher among plain AAS abusers than among controls (Table 3, Study I). No signiÞ cant 
differences were present between the subjects using only AAS and those using both AAS and GH in the 
period of lifetime AAS abuse or the duration of the previous cycle (Table 2, Study I).
Among the controls, the correlation between LV mass and body weight was high (r=0.72, 
p<0.01). In contrast, correlations among anabolic substance abusers (n=20) between LV 
mass and the persons height (r=0.24), weight (r=0.32), resting heart rate (r=0.09), systolic 
(r=-0.14) and diastolic blood pressure (r=0.22), period of lifetime AAS abuse (r=0.27) or length of AAS 
use prior to cardiac evaluation (r=0.13) were low and non-signiÞ cant (Table 4, Study I). However, the 
correlation coefÞ cient between LV mass and mean AAS dose was high (r=0.54, p<0.015) (Figure 12).
When the simultaneous effects of background factors on LV mass in substance-abusing power athletes 
(n=20) were investigated, subjects physical characteristics, AAS abuse characteristics (period of 
lifetime AAS abuse, length of AAS use prior to cardiac evaluation, mean AAS dose), blood pressure 
and resting heart rate were included as independent variables in a forward stepwise regression analysis. 
The three factors constituting the Þ nal model were mean AAS dose, age and systolic blood pressure, 
accounting for 29%, 14% and 17%, respectively, of the variance in LV mass.
One of the subjects was studied three times: when he used both AAS and GH; then 237 days later, when 
he was not abusing any substances; and when he resumed abusing AAS alone. On these occasions, his 
LV mass was 3.8, 2.3 and 3.1 of his body weight, respectively (Figure 2, Study I).
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To study LV diastolic function, the early peak ß ow velocity (E) and peak atrial ß ow velocity (A) were 
measured and the E/A ratio calculated. This ratio did not signiÞ cantly differ between the groups. Among 
the substance abusers (n=20) the E/A ratio correlated negatively with the persons age (r=-0.70, p<0.01), 
height-indexed LV mass (r=-0.49, p<0.05) and RelWT (r=-0.60, p<0.01). A negative correlation was 
found between the E/A ratio and diastolic blood pressure (r=-0.49, p<0.05). RelWT correlated positively 
with resting diastolic blood pressure (r=0.58, p<0.05) (Table 4, Study I).
Both endurance (n=30) and power athletes abusing AAS (n=15, Study II) had signiÞ cantly greater wall 
thickness and cavity dimensions than the sedentary controls (Table III, Study II). The shape of the 
LV chamber was comparable in all groups, as revealed by the equal ratio of LV diameter to length. On 
average, LV mass was 56 % greater in the endurance and 72% greater in the power athletes than in the 
controls (Table III, Study II). When expressed in relation to body surface area, the endurance athletes 
had 9% greater LV mass than the power athletes. Among all subjects (19 power athletes, 30 endurance 
athletes, 15 sedentary controls), RelWT is signiÞ cantly correlated with LV mass (r=0.56, p<0.001) 
(Figure 13).
8.2. Effects on QT dispersion
The endurance athletes (n=30) had the lowest heart rates, and the power athletes (n=15) and controls 
(n=15) had similar heart rates on the average (Table II, Study II). Resting blood pressures were 
comparable between all three groups. Endurance athletes had the longest QT intervals in every lead, 
the differences being highly signiÞ cant even when QT intervals were adjusted for heart rate (Table IV, 
Study II). The power athletes had shorter QT intervals than the controls, but the difference did not reach 
statistical signiÞ cance (Table IV, Study II). This Þ nding was also consistent over all 12 leads. When 
adjusted for heart rate, the power athletes still had the shortest QT intervals, but when compared with 
controls, the differences remained signiÞ cant in only four leads.
The power athletes exhibited the greatest amount of QT dispersion and the endurance athletes the least. 
When the dispersion was expressed as a percentage of the longest QT interval duration or as the standard 
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deviation of the QT interval divided by the mean QT interval, the differences between the groups were 
clearly accentuated (Table IV, Study II).
Overall, no signiÞ cant correlation was present between LV mass and QT dispersion. Low, although 
statistically signiÞ cant correlations were found between QT dispersion and E/A ratio (r= -0.30), and 
LV end-diastolic diameter (r= 0.26) but not with LV mass. E/A ratio was signiÞ cantly smaller in power 
athletes than in endurance athletes (mean ± SD; 1.59 ± 0.40 vs. 2.39 ± 0.61, p<0.001).
8.3. Effects on cholesterol metabolism
HDL cholesterol concentrations were 52% lower (p<0.05) during AAS abuse than during the withdrawal 
period (Table 8).
AAS abuse signiÞ cantly increased serum ubiquinone concentration by 47% (p<0.05). Moreover, a high 
positive correlation was found between serum ubiquinone concentration and daily steroid dose (r=0.76, 
p<0.05, n=8) (Figure 14). A high negative correlation was present between the ubiquinone and HDL 
cholesterol concentrations (r=-0.66, p<0.05, n=11) (Figure 15).
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Serum dolichol concentrations, by contrast, were 17% lower during AAS abuse than during withdrawal 
(Table 8). Daily steroid dose correlated negatively with serum dolichol concentration, but the 
correlation did not reach statistical signiÞ cance (r=-0.60) (Figure 14). HPLC proÞ les of the dolichol 
fractions remained conctant throughout the AAS abuse and withdrawal periods.
8.4. Effects on collagen metabolism
In Study IV, the measured serum PICP, ICTP and PIIINP concentrations were within reference ranges 
for healthy adult males (Table 9).
Serum PIIINP concentrations during the abuse of AAS and one month after cessation were signiÞ cantly 
higher than values obtained two months after cessation (Table 9). Serum ICTP measured after one 
month of AAS abuse was 3.10 ± 1.48 as compared with 3.90 ± 1.71 after one month of withdrawal. 
There was a borderline signiÞ cance in differences in this type I collagen degradation (Repeated Measure 
of ANOVA, p= 0.057). No correlation was found between serum ICTP and urine LP.
The urine HP/LP ratio correlated positively with weight-indexed AAS dose (r=0.56, p<0.05, n=16) 
(Figure 16). Urine excretion of creatinine measured after two months abuse was signiÞ cantly higher 
than values obtained after one months abuse or during the withdrawal period (Table 4, Study IV).
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8.5. Effects on spermatogenesis
In Study V, subjects age had no signiÞ cant inß uence on sperm concentration in any sample among our 
study population (Sample 1: r=-0.46, p=0.10; Sample 2: r=-0.30, p=0.29; Sample 3: r=-0.37, p=0.19). 
Nor was any association found between any semen variable and the length of lifetime AAS abuse 
(Table 10).
At the end of the AAS cycle (n=18), sperm count was 33 ± 49 x106/ml (mean ± SD) (median 11 x106/
ml), and one subject was diagnosed with azoospermia. After 1½ months of cessation of AAS cycles 
(n=16), sperm concentration was 30 ± 42 x106/ml (median 7 x106/ml). Six months after the cessation of 
AAS abuse (n=16), the mean number of spermatozoa had increased to 77 ± 70 x106/ml (median 73 x106/
ml) (95% CI 40-115 x106/ml). One of the subjects was diagnosed as azoospermic throughout withdrawal 
period; his sperm count even exceeded normal limits during the AAS cycle. The differences between the 
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samples drawn six months after cessation of AAS abuse and both during and 1.5 months after the abuse 
were signiÞ cant (p≤0.05, Repeated Measures of ANOVA) (Table 3, Study V).
In semen samples taken at the end of the AAS cycle, the correlation between sperm concentration and 
mean daily AAS dose nearly reached the level of statistical signiÞ cance (r=-0.44, p=0.066) (Figure 2, 
Study V). A signiÞ cant positive correlation was observed between HCG dose used during the cycle and 
the percentage of morphologically abnormal spermatozoa (r=0.60, p<0.01) (Figure 2, Study V).
When simultaneous background factors of morphologically abnormal spermatozoa were investigated, 
the HCG dose used was the only factor bearing signiÞ cance in the model, accounting for 36.5% of the 
variance. In subjects using a higher dose of HCG, spermatozoa were signiÞ cantly morphologically 
abnormal [mean: 80% vs. 28% (higher vs. lower)], although the higher HCG dose maintained 
spermatogenesis better during the cycle, the sperm concentration being 44 ± 54 x106/ml (mean ± SD) 
(median 21 x106/ml) vs. 10 ± 17 x106/ml (median 0.6 x106/ml) (p<0.05). No differences were present 
between the HCG groups in AAS dose.
Before starting the study, Þ ve of the 18 subjects reported having one or more children. Six years after 
completing the study, 10 of the subjects had got children and one couple had terminated a pregnancy 
after the study.
The main Þ ndings are summarized Table 11.
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9. DISCUSSION
Several adverse effects of massive doses of AAS were detected in this series of studies, which were 
performed under authentic conditions of anabolic substance abuse. Novel Þ ndings were that abuse of 
AAS, especially with GH, resulted in marked pathological hypertrophy of the myocardium, which 
was observed as a signiÞ cant concentric remodeling of LV and increased QT dispersion. Also, serum 
ubiquinone concentration was signiÞ cantly increased during AAS abuse
In line with previous studies, LDL/HDL cholesterol ratio was signiÞ cantly increased and, also, all of our 
subjects demonstrated hypogonadotrophic hypogonadism while on AAS. Although some subjects were 
able to maintain spermatogenesis during AAS abuse with regular injections of HCG, semen quality was 
impaired. After six months of AAS abstinence, mean semen concentrations reached the normal level, 
but mean serum testosterone concentrations remained low. 
AAS abuse is suspected to result in Þ brous tissue formation in the myocardium (Nieminen et al. 1996). 
Our results suggest that AAS abuse at supraphysiological doses decreases the degradation of type I 
collagen and signiÞ cantly increases the overall metabolism of type III collagen in all soft tissues. 
Deleterious effects with massive doses of AAS were seen on various organs and metabolic systems 
strengthening the idea of dose-dependent adverse effects.
Knowledge of adverse effects of AAS at supraphysiological doses in the past has been mainly based on 
animal experiments and case reports. Some previous reviews have been speculating that most harmful 
adverse effects of AAS abuse are those that affect cardiovascular and reproductive systems (Lucas 
1993, Taimela & Seppälä 1994, Pärssinen & Seppälä 2002). The Þ ndings of the present study indicate 
several, potentially life-threatening adverse effects of anabolic substance abuse, strengthening the 
evidence from the previous Þ ndings. Exercise-associated health beneÞ ts may not be gained when the 
training regimen is augmented with anabolic substances abuse. Weight training itself does not decrease 
life expectancy, but the substance abuse often associated with it can increase the risk of premature death 
(Sarna et al. 1993, Pärssinen et al. 2000).
9.1. Study limitations
Several limitations were encountered due to nature of this study, with the subjects primary aim being 
to improve physical Þ tness and increase muscle mass. To reveal the health problems connected with 
this particular subculture abusing doping substances under authentic conditions, the limitations had to 
be accepted. For ethical reasons, controlling the use of steroids or the dosage or pharmaceutical agents 
chosen was not possible since the drug abuse occurred independently of this study. To compare the use 
of moderate and massive doses of AAS, we divided the subjects into groups based on self-reported 
substance abuse information.
Most previous studies used a similar follow-up method, and they also suffer from a lack of a matching 
control group. Arranging a matching control group with a reliable history of power training without 
any abuse of anabolic substances seems practically impossible due to the secretive nature of substance 
abuse. Moreover, training histories and training volumes of these groups would not be comparable. 
The number of subjects in the present study (26) is high compared with previous studies of a similar 
design. In addition, the duration of follow-up, 2-9 months of drug abuse and 5-9 months of withdrawal, 
was longer than in most earlier studies. Overall, our subject sample is reasonably representative of this 
highly selective group of subjects.
We were unable to control for the effects of training on the myocardium and on other parameters, 
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although the subjects maintained a similar heavy load resistance-training regimen throughout the study. 
All subjects had been practicing with weights for at least two years prior to the study. Diet was also not 
controlled, but subjects reported the diet having remained unchanged. In studies where recruitment is 
based on voluntariness, without controlling the substances abused, selection bias is inevitable. However, 
subjects with a medical history of diseases associated with the systems studied were excluded, and all 
underwent medical examination, after which only clinically healthy subjects were included.
9.2. Effects on cardiovascular system
LV mass, geometry and Þ lling were studied among abusers of anabolic substances with echocardiography. 
Myocardial hypertrophy was evident and was dose-dependently associated with AAS abuse, and 
concomitant use of GH led to an even greater increase in LV mass. LV mass was unrelated to body 
dimensions among the subjects, although in the controls, a signiÞ cant positive correlation was found. 
This supports the idea that AAS and GH have a direct effect on the myocardium. Several earlier studies 
also suggest that GH or concomitant IGF-I has a direct effect on the myocardium (Lie 1980, Mathews et 
al. 1989). Moreover, the GH receptor gene is expressed in the rat myocardium (Mathews et al. 1989).
A signiÞ cant proportion of patients with GH hypersecretion, i.e. acromegaly, demonstrate LV 
hypertrophy, even without hypertension. Acromegalic heart enlargement does not correlate with body 
weight or height (Lie 1980). In GH-deÞ cient adults, GH substitution increases LV mass mainly by 
increasing LV dimensions (Caidahl et al. 1994). On the other hand, suppressing GH hypersecretion in 
acromegaly with the somatostatin analogue octreotide causes a signiÞ cant decrease in LV mass without 
altering body dimensions (Lim et al. 1992).
Strenuous physical exercise is known to increase LV mass (Maron 1986). According to Pellicicia et al. 
(1991, 1993), LV wall thickness exceeding 13 mm is uncommon in highly trained competitive athletes, 
and thus, its occurrence would suggest an explanation other than intensive athletic training. This study 
supports the conclusion because 4 out of 20 subjects (3 of whom concomitantly used GH) had an LV 
wall thickness greater than 13 mm. One can therefore reason that part of the myocardial hypertrophy 
observed in the subjects is due to self-administration of anabolic substances.
Our Þ nding is in line with previous reports that AAS alter the LV morphology, making it more 
concentric (Dickerman et al. 1997a,c), and that concomitant abuse of GH leads to an even greater 
RelWT of LV. Isometric weight training is assumed to increase concentric LV hypertrophy, whereas 
endurance training is assumed to be associated with eccentric LV hypertrophy (Shapiro 1984, Maron 
1986). Contrary reports are also available in which AAS-abusing power athletes demonstrate both 
concentric and eccentric enlargement of LV mass (Deligiannis & Mandroukas 1992, Sachtleben et al. 
1993), in accordance with our Þ ndings. In fact, our echocardiographic Þ ndings in power athletes using 
massive doses of AAS but not GH resembled Þ ndings in top-level endurance athletes. We demonstrated 
that concentricity of LV is associated with LV mass.
Despite similarities in echocardiographic Þ ndings, substance-free endurance athletes and AAS-abusing 
power athletes differ markedly with respect to their electrocardiographic repolarization indices. 
Physiological LV hypertrophy in endurance athletes not using drugs did not increase QT dispersion, 
which has been shown to be associated with a pathological myocardium (Mayet et al. 1996, Perkiömäki 
et al. 1996). While QT intervals were prolonged in endurance athletes, they had signiÞ cantly less QT 
dispersion. AAS users had the shortest QT intervals of all study groups but a greater QT dispersion.
The physiological lengthening of the QT interval, which has earlier been shown to also exist in female 
endurance athletes, may have two potential mechanisms (Stolt et al. 1997). First, physiologically adapted 
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LV hypertrophy could prolong the process of repolarization. Second, endurance athletes have enhanced 
vagal tone, which may lengthen the QT interval (Browne et al. 1984). Pathological hypertrophy of LV 
induced by AAS abuse does not demonstrate vagal bradycardia (author´s unpublished observation).
LV hypertrophy among power athletes was not physiological since it was partly induced by anabolic 
substances. This pathological hypertrophy was reß ected as an increased dispersion of QT intervals, 
similar to that found in hypertensive LV hypertrophy (Mayet et al. 1996, Perkiömäki et al. 1996). It may 
also be reß ected as a higher risk of malignant arrhythmia in AAS users. Two of the subjects participating 
in this study did show increased fat and Þ brous tissue in endomyocardial biopsies, with one of these 
subjects experiencing exercise-induced ventricular tachycardia during the treadmill test (Nieminen et 
al. 1996). Thus, the LV mass as such is not a determinant of the QT variables, rather it is the histological 
quality of the myocardium that is decisive.
Cardiac systolic function has been reported to remain normal during AAS administration (Deligiannis 
et al. 1992), but there are contradictory reports concerning AAS effects on diastolic function (Pearson et 
al. 1986, Urhausen et al. 1989, Thompson et al. 1992, Dickerman et al. 1998). While we did not Þ nd any 
signiÞ cant differences in the E/A ratios between study groups, the four subjects using both AAS and GH 
tended to have lower E/A ratios, demonstrating impaired diastolic LV function. Impaired diastolic Þ lling 
has also been reported in the active phase of acromegaly (Smallridge et al. 1979, Rossi et al. 1992). The 
subject who underwent echocardiography three times over a period of 20 months showed alterations 
in the E/A ratio between cycles; he had the lowest E/A ratios while using anabolic substances and the 
highest during the withdrawal period.
Our Þ ndings suggest that AAS and GH have very similar anabolic effects on the myocardium, and 
these two anabolic substances seem to potentiate the hypertrophic effect when used concomitantly. 
In earlier experimental studies, a similar effect of concomitant administration of androgens and GH 
has been demonstrated (Scow & Hagan 1965). This effect may be mediated through AAS decreasing 
the circulating levels of IGF-bp3, leading to increased concentrations of free GH and IGF-1 (Karila 
et al. 1998). However, Alén et al. (1985) found that serum GH concentrations were increased during 
AAS abuse without exogenous GH administration. It has also been speculated that androgen receptor 
concentration may depend on GH concentration (Krieg et al. 1978). However, these two anabolic agents 
clearly possess a profound deleterious direct effect on the human myocardium when concomitantly 
abused and may predispose the abuser to a premature cardiac event (Figure 17).
9.3. Effects on lipid metabolism
In addition to myocardial changes, AAS also affect metabolic systems connected with the 
cardiovascular system. Serum HDL levels are very low in AAS users, predisposing to premature 
atherosclerosis (Alén & Rahkila 1984, Webb et al. 1984, Glazer 1991). Several earlier reports have 
also indicated increased risk of arterial thrombosis during AAS use (Ferenchick et al. 1992, Gaede et 
al. 1992), but the speciÞ c pathomechanism remains to be elucidated (Ferenchick 1991, Nakao et al. 
1991, Thorisdottir et al. 1992, Polderman et al. 1993). Our Þ ndings conÞ rm that abuse of AAS results 
in profound alterations in serum HDL cholesterol concentrations. According to the study groups 
clinical experience, orally administered 17α-alkylated steroids appear to produce a greater reduction 
on HDL concentration than 17β-esters. 
No previous studies have elucidated the effect of supraphysiological doses of AAS on the non sterol 
isoprenoid compounds ubiquinone and dolichol, which are by-products of the synthetic pathway of 
cholesterol (Olson & Rudney 1983). These isoprenoids may have an effect on the regulation of cell 
growth, but their exact physiological role is unclear (Siperstain 1984).
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Exogenous ubiquinone is administered because of its presumed preventive role in atherosclerosis and to 
enhance aerobic capacity in athletes. Ubiquinone acts as a lipid-soluble electron carrier in the electron 
transport chains of mitochondria (Olson et al. 1983). Its reduced form, ubiquinol, has a powerful 
antioxidant effect on LDL, and therefore, it is hypothesized to protect against atherosclerosis (Stocker 
et al. 1991). In this study, a signiÞ cant rise in serum ubiquinone level was observed during AAS abuse, 
and the rise was even greater than that measured during oral administration of ubiquinone preparations 
(Laaksonen, personal communication). The atherogenic changes due to AAS abuse can be assumed to be 
partly countered by increased ubiquinone concentration. Ubiquinone is mainly carried in the circulation 
by LDL (Laaksonen et al. 1995). In earlier studies, the ubiquinone/LDL ratio has been invariable under 
all investigated conditions (Karlsson et al. 1989, 1990). In the present study, a correlation was also 
found between serum ubiquinone and LDL concentrations (r=0.54, p=0.054).
Dolichols are α-saturated polyisoprenoid alcohols that are synthesized in microsomes and stored in 
lysosomes (Rip et al. 1985), and the liver appears to regulate its circulatory dolichol supply (Marino 
et al. 1994). In phosphorylated form, dolichols function in the biosynthesis of glycoproteins, also 
modifying biological membrane ß uidity, stability, permeability and fusion (Lai & Schutzbach 1984, 
Rip et al. 1985, Valtersson et al. 1985). In a manner dissimilar to that observed for ubiquinone, serum 
dolichol concentration decreased during AAS abuse. Dolichols are transported in the circulation mainly 
by HDL (Yasuki & Oshima 1994). In the present study, the serum dolichol/HDL ratio remained virtually 
unchanged regardless of AAS use. This could be due to common regulatory mechanism for HDL.
Isoprenoids have been shown to be involved in controlling cell growth (Siperstain 1984). 
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Further studies have revealed that isoprenylation of growth-regulating proteins produces a 
potential signalling factor for cellular proliferation (Santos & Nebreda 1989, Mendola & Baker 
1990). Altered isoprenoid production due to AAS use may lead to interference with the cellular 
proliferation mechanism. Changes in isoprenoid metabolism may explain some anabolic effects 
of AASs or may be a launching mechanism for uncontrollable growth. The abuse of AAS has 
been associated with various tumor formations (Lesna & Taylor 1986). Increased isoprenoid 
metabolite concentration may have a role in AAS-induced promotion of tumor growth.
9.4. Effects on collagen metabolism
AAS have a quantitative and qualitative effect on connective tissue, which is made up of various collagen 
Þ brils (Michna 1986, Laseter & Russell 1991, Inhofe et al. 1995). Fibrous tissue in the myocardium 
has been shown to be increased with AAS use (Nieminen et al. 1996). Further, AAS abuse has been 
demonstrated to weaken tendons and ligaments, exposing muscles and tendons to ruptures (Kramhøft & 
Solgaard 1986, Bach et al. 1987). Among AAS-abusing athletes, tendon and muscle insertion traumas 
are more frequent (Taimela & Seppälä 1994). Moreover, duration of exposure to AAS also seems to 
have an effect on quality of collagen Þ brils (Michna 1986). However, tendons and muscle insertions are 
put under greater demands with increased muscle strength and consequently, decreased collagen quality 
may predispose these structures to ruptures. This study protocol did not examine the effect of increased 
load on tendon.
High doses of AAS were found to enhance collagen synthesis, especially in soft connective tissues. 
During the AAS cycle soft connective tissue collagen metabolism was increased. This effect tended to 
be dose-dependent. Degradation of type I collagen, by contrast tended to diminish; collagen type I is 
most abundant in bone tissue (Melkko et al. 1990). Urinary lysylpyridinoline (LP) mature crosslinks 
of collagen values remained unchanged. An increase in urinary LP values is generally considered to 
be a marker of collagen metabolism in bone tissue. In our study, collagen originating from bone was 
unaffected by AAS abuse, at least within the time interval evaluated. Concordant with this, the elevated 
urinary HP/LP mature crosslinks of collagen ratios during AAS abuse compared with values obtained 
during the withdrawal period suggest that the collagen increase originated from the degradation of soft 
connective tissue. Muscle mass was exceptionally high in our subjects, and because connective tissue in 
muscle can be a considerable source of HP (Fujimoto 1980, Palokangas et al. 1992, James et al. 1993), 
it was not unexpected that increased collagen metabolism result in an AAS-induced anabolic effect on 
muscle tissue over the time frame. 
The mechanism of action of supraphysiological AAS doses on tissue metabolism remains unclear. Most 
of the androgen effects on bone turnover and bone mass have been suggested to occur via the estrogen 
receptor, with prior aromatization of androgens into estrogens (Vanderschueren et al. 1995). This may 
be the case in the present study. Alén at al. (1985) had measured increased estrogen concentrations in 
males taking AAS. AAS at high concentrations may also bind to glucocorticoreceptors, and thus, the 
effects of AAS on collagen may occur by reversing the effects of corticosteroids (Rogol et al. 1992, 
Haupt 1993). 
Serum PICP has been used a marker for osteoporosis in clinical practice. Although AAS administration 
is indicated in treating osteoporosis, we were not able to demonstrate changes in serum PICP regardless 
of the AAS dosage. This may be due to the relatively short duration of the study. We did, however, 
conÞ rm that AAS have at least a qualitative effect on collagen metabolism in soft connective tissue. 
These short-term changes in collagen metabolism may be due to increased anabolic effects in muscle or 
may be secondary effects of increased working capacity.
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9.5. Effects on reproductive system
In agreement with previous studies, we found that abuse of supraphysiological doses of AAS results 
in transient severe oligozoospermia in males due to AAS-induced reversible hypogonadotrophic 
hypogonadism (Alén & Suominen 1984, Schurmeyer et al. 1984, Jarow & Lipshultz 1990). But contrary 
to these reports, our results also suggest that concomitant use of AAS and HCG cause deteriorated 
semen quality. This is in accordance with the recent Þ nding of Torres-Calleja et al. (2001) that abuse of 
AAS alone not only reduces the sperm concentration but also impairs the percentage of morphologically 
normal semen.
All subjects were aware of the side-effects associated with substance abuse. In Finland, steroid abusers 
are accustomed to using one HCG injection (2500-5000 IU) a month during the cycle. Larger doses are 
used at the end of an AAS cycle; 10 000-20 000 IU of HCG divided into two to four separate injections, 
are typically used during the last two weeks of the cycle (authors unpublished data). In addition, some 
of our subjects used antiestrogens such as tamoxifen (10-20 mg/day) or clomifen (50-100 mg/day) to 
treat and prevent gynegomastia. Power athletes also use antiestrogens in the belief that they maintain 
gonadal function during the steroid cycle and promote faster hormonal recovery from AAS abuse. Our 
Þ ndings indicate that antiestrogens used during the AAS cycle do not increase serum gonadotropin 
concentrations
The mean duration of the AAS cycle was 4½ months and the mean daily dose of AAS was 96 mg, and 
only one subject became azoospermic soon after cessation of abuse. In a multicentre male contraception 
study conducted by WHO (1990), up to 65% of subjects became azoospermic during the six-month 
suppression period with a mean daily dose of 29 mg of testosterone enanthate. In our study, the mean 
daily dose of AAS seemed to have more effect on sperm concentration than did cycle duration. Alén 
& Suominen (1984) demonstrated azoospermia (6 out of 7) after three months of AAS abuse without 
HCG use, at a mean daily dose of 50 mg. Most of their subjects reached azoospermia at even lower AAS 
dosing and within a shorter period of time. One can therefore conclude that combined use of HCG and 
AAS can maintain endogenous spermatogenesis during AAS abuse.
In male contraception studies, the recovery of sperm concentration to baseline levels has been found to 
take about six months (WHO 1990). Most of our subjects also achieved normal sperm density after the 
six-month withdrawal period. Uppon cessation of substance abuse, one subject became azoospermic 
and did not recover during the six-month withdrawal. However, during the Þ ve-year follow-up the 
subject and his wife had conceived two healthy daughters.
Although spermatogenesis was recovered by most of the subjects during the six-month withdrawal 
period, serum testosterone concentrations did not reach normal levels among the heaviest AAS 
abusers. Alén et al. (1985b) reported that during a withdrawal period of 3 to 4 months subjects´ serum 
testosterone failed to reach normal levels even though gonadotrophin concentrations were within 
normal limits, indicating prolonged impairment of testicular function. This is consistent with the Þ nding 
that long-term AAS abuse may produce transient testicular impairment, which can be seen in lowered 
serum testosterone and testosterone precursor levels with normal gonadotrophin stimulus (Ruokonen et 
al. 1985). We were able to demonstrate similar Þ ndings in subjects with a long history of AAS abuse, 
especially in those using massive dosages. Despite impaired steroidogenesis, these subjects had normal 
spermatogenesis after the withdrawal period. Further, the subjects did not suffer from any subjective 
symptoms that might have accounted for the testosterone deprivation. 
In normal adult males with normal spermatogenesis, testosterone concentrations in the testes are 50-fold 
higher than in peripheral serum (Turner et al. 1984, Adamopoulos et al. 1997). One could hypothesize 
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that the required concentration could also be achieved by back ß ow of androgens from the circulation 
to the testes when massive doses of AAS are abused.
During transient hypogonadotrophic hypogonadism induced by abuse of AAS steroidogenesis seems to 
respond to HCG in a similar way as in prepubertal boys (Martikainen et al. 1986). Our study demonstrates 
that spermatogenesis can be maintained by using HCG regardless of AAS-induced suppression of 
gonadotrophin secretion. This Þ nding is in line with the observation that normal spermatogenesis 
could be maintained with HCG after three months´ suppression of steroidogenesis with testosterone 
(Matsumoto et al. 1983). Normal sperm quality can be achieved with HCG alone in men who have 
hypogonadotrophic hypogonadism at postpubertal onset (Finkel et al. 1985). Our results suggest that 
HCG maintains spermatogenesis in AAS abusers with no FSH stimulus, but this regimen produces more 
abnormal and hypokinetic spermatozoa. This reduced semen quality may be due to lowered FSH, which 
has at the very least a quantitative role in human spermatogenesis (Tapanainen et al. 1997). However, 
HCG alone has also been shown to have a direct effect on spermatogenesis, resulting in poorer sperm 
quality (Dunkel et al. 1997). Other contrary reports that indicate when HCG was administered to 
patients with idiopathic oligo- or asthenozoospermia without hypothalamohypopituitary-hypogonadism 
47% showed improvement in semen quality, mainly in motility and morphology (Homonnai et al. 
1978). Sperm quality impairment in the present study cannot be explained by altered excretion of 
gonadotrophins, leaving concomitant abuse of AAS and HCG as a viable explanation.
9.6. Clinical implications
The use of performance-enhancing substances is associated with a higher risk for cardiac events and 
sudden death, which can be partly explained by pathological myocardial hypertrophy and subsequent 
increased QT dispersion.
AAS abuse induces a marked increment to the LDL/ HDL ratio, which is considered to be a marker 
of increased risk for atherogenic cardiovascular disease. However, atherogenic changes may in part be 
counteracted by the increased ubiquinone to dolichol ratio induced by AAS. 
AAS use may expose abusers to soft tissue traumas due to altered collagen metabolism in those tissues. 
AAS abuse may induce direct effects on collagen metabolism, and also inß uence tendons and tendon 
insertions indirectly due to the increased working capacity of muscles.
AAS-impaired spermatogenesis is reversible, but may involve a lengthy recovery especially if long-
acting AAS are used.
Although subjects were thoroughly counseled about the risks associated with substance abuse, all 
continued the abuse after the six-month withdrawal period. Even a subject who sustained an episode of 
ventricular tachycardia, which was treated with electronic cardioversion, continued a training regimen 
augmented with various anabolic substances. Contradictory evidence exists about the effectiveness of 
counseling against the substance abuse (Goldberg et al. 1996, OSullivan et al. 2000, Nilsson et al. 
2001b). It was obviously that the lack of convincing evidence of adverse effects associated with abuse 
that was the major reason for the ineffectiveness of counseling with this selected group pf AAS abusers. 
Hence, more studies are needed to convince abusers to avoid the long-term adverse effects of abuse of 
anabolic substances.
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10. CONCLUSIONS
Cardiovascular, metabolic and male fertility aspects associated with anabolic substance abuse were 
investigated. The effects of abuse, particularly of massive doses of anabolic androgenic steroids with or 
without concomitant abuse of the most common subsidiaries, were also evaluated. Taken together, the 
studies conÞ rm that the abuse of anabolic substances produces profound, partly irreversible changes in 
various organs and systems, and that these changes tend to be dose-related.
The main conclusions are as follows:
1. Abuse of anabolic androgenic steroids induces dose-related left ventricular hypertrophy, and 
the concomitant abuse of growth hormone is associated with concentric remodeling of the left 
ventricle. The morphological changes resemble those of endurance athletes but show pathological 
features. Other factors, such as endocrinological or genetic components, may have a stronger role 
in the morphological adaptation of the myocardium to exercise than type of training.
2. Abuse of anabolic androgenic steroids increases QT dispersion measured by a 12-lead 
electrocardiogram. The left ventricular mass as such is not a determinant of the QT variables, but 
the morphological and histological qualities of the myocardium impact on QT variables and alter 
repolarization of the myocardium.
3. In line with previous reports, the abuse of anabolic androgenic steroids was found to induce 
profound changes in serum lipid concentrations. Serum high-density lipoprotein concentration 
during abuse at the highest doses was under the detection limit of the laboratory method used. 
The inß uence on cholesterol metabolism seems to be related to by-products of the mevalonate 
pathway. Serum concentration of ubiquinone is signiÞ cantly increased without inß uencing serum 
low-density lipoprotein concentration.
4. Supraphysiological doses of anabolic androgenic steroids enhance collagen synthesis, especially in 
soft connective tissues, probably due to increased anabolic action in muscle tissue.
5. Concomitant abuse of supraphysiological doses of anabolic androgenic steroids with human 
chorionic gonadotrophin results in profound alteration of semen density. Anabolic androgenic 
steroids induce hypogonadotrophic hypogonadism, and combined with human chorionic 
gonadotrophin can maintain spermatogenesis but reduce semen quality. The abuse of anabolic 
substances results in transiently lowered male fertility, but the reduced semen density and semen 
quality appears to be reversible.
The subjects were followed for approximately one year, and despite receiving abundant information 
concerning their health status, none discontinued doping substance abuse after the study. This highlights 
the need for effective educational programme to discontinue the abuse. Because the more commonly 
abused anabolic substances increase the risk for cardiac event and lower male fertility, the abuse of such 
substances should be considered a public health problem.
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